Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  1  
  
 
 
 
 
A PHASE  2B, PLACEBO -CONTROLLED,  RANDOMIZED,  OBSERVER -BLINDED 
TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND 
IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS 
VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, 
DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY 
NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE  
 
Study  Intervention  Number:  PF-06760805  
Study Intervention Name:  Group B Streptococcus 6 -Valent 
Polysaccharide  Conjugate  Vaccine  (GBS6)  
US IND Number:  CCI  
EudraCT  Number:  Not Applicable  (N/A)  
Protocol  Number:  C1091005  
Phase:  2b 
Brief  Title:  Group  B Streptococcus  Vaccine  and Concomitant  Administration  of Tdap  in 
Nonpregnant Women  
 
 
This document  and accompanying  materials  contain  confidential  information  belonging  to Pfizer.  Except  as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law) or 
use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.  

Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  2  
 Document  History  
 
Document  Version  Date  
Amendment  3 04 October  2022  
Amendment  2 11 April  2022  
Amendment  1 22 January  2021  
Original  protocol  08 December  2020  
 
This amendment incorporates all revisions to date, including amendments made at the 
request  of country  health  authorities  and IRBs/ECs  and any protocol  administrative  change 
letter(s).  
Protocol  Amendment  Summary  of Changes  Table  
Amendment  3 (04 October  2022)  
Overall Rationale for the Amendment : The addition of Visit 3 will be a 6 -month safety 
follow -up telephone  call. Visit  3 is added  to address  CBER’s  request  for a 6-month  safety 
follow -up. 
 
Section  # and Name  Description of Change  Brief Rationale  
Section 1.1 : Synopsis 
Section  1.3: Schedule  of 
Activities  
Section  3: Objectives,  Estimands, 
and Endpoints  
Section 4.1 : Overall Design 
Section 5.2 : Exclusion Criteria 
Section 6.5.3 : Recording 
Nonstudy Vaccinations and 
Concomitant Medications 
Section 8.3.1 : Time Period and 
Frequency  for Collecting  AE and 
SAE Information  
Section  8.3.5.1 : Exposure  During 
Pregnancy  
Section  8.11.3 : Visit  3 – 6-Month 
Telephone Call Follow -up Visit 
(160-200 Days After Visit 1)  
Section  8.11.4 : Unscheduled 
Visits  • The addition of 
Visit  3 will be a 
6-month safety  
follow -up telephone 
call. • A 6-month safety 
follow -up telephone 
call has been  added  to 
address CBER 
feedback.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  3  
  
Section  # and Name  Description of Change  Brief Rationale  
Section 9.1.2 : Estimands 
Section  9.5: Interim  Analyses 
Section 10.6 : Appendix 6: 
Protocol  Amendment  History    
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  4  
 TABLE  OF CONTENTS  
LIST  OF TABLES  ................................ ................................ ................................ .....................  8 
1. PROTOCOL  SUMMARY  ................................ ................................ ................................ ..... 9 
1.1. Synopsis  ................................ ................................ ................................ .....................  9 
1.2. Schema ................................ ................................ ................................ .....................  13 
1.3. Schedule  of Activities  ................................ ................................ ..............................  14 
2. INTRODUCTION  ................................ ................................ ................................ ................  16 
2.1. Study  Rationale  ................................ ................................ ................................ ........  16 
2.2. Background  ................................ ................................ ................................ ..............  16 
2.2.1.  Disease  Overview  ................................ ................................ ........................  16 
2.2.2.  Maternal  Immunization as  an Approach to Prevent Disease in Infants  
and Pregnant  Women  ................................ ................................ .......................  17 
2.3. Benefit/Risk Assessment  ................................ ................................ .........................  18 
2.3.1.  Risk Assessment  ................................ ................................ .........................  19 
2.3.2.  Benefit Assessment  ................................ ................................ .....................  21 
2.3.3.  Overall Benefit/Risk Conclusion  ................................ ................................  21 
3. OBJECTIVES,  ESTIMANDS,  AND  ENDPOINTS  ................................ ............................  21 
4. STUDY  DESIGN  ................................ ................................ ................................ .................  24 
4.1. Overall  Design  ................................ ................................ ................................ .........  24 
4.2. Scientific Rationale for Study  Design  ................................ ................................ ..... 24 
4.3. Justification for Dose  ................................ ................................ ...............................  24 
4.4. End of Study  Definition  ................................ ................................ ...........................  25 
5. STUDY POPULATION  ................................ ................................ ................................ ...... 25 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ..... 25 
5.2. Exclusion Criteria  ................................ ................................ ................................ .... 26 
5.3. Lifestyle  Considerations  ................................ ................................ ..........................  27 
5.3.1.  Contraception  ................................ ................................ ..............................  27 
5.4. Screen  Failures  ................................ ................................ ................................ ........  27 
5.5. Criteria for Temporarily  Delaying  
Enrollment/Randomization/Administration of Study  Intervention  ...........................  28 
5.5.1.  Temporary  Delay  Criteria  ................................ ................................ ...........  28 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  5  
 5.5.1.1.  Criteria   for  Temporarily   Delaying   Vaccine  
Administration  ................................ ................................ ..................  28 
5.5.1.2.  Criteria  for Temporarily  Delaying  Blood  Draw  ........................  28 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................ . 28 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ........  28 
6.1.1.  GBS6  ................................ ................................ ................................ ..........  29 
6.1.2.  Tdap  ................................ ................................ ................................ ...........  29 
6.1.3.  Placebo  ................................ ................................ ................................ ....... 29 
6.1.4.  Administration  ................................ ................................ ............................  29 
6.2. Preparation/Handling/Storage/Accountability  ................................ .........................  30 
6.2.1.  Preparation  and Dispensing  ................................ ................................ ........  31 
6.3. Measures  to Minimize  Bias:  Randomization  and Blinding  ................................ .... 32 
6.3.1.  Allocation  to Study Intervention  ................................ ................................  32 
6.3.2.  Blinding  of the Site Personnel  ................................ ................................ .... 32 
6.3.3.  Blinding of the Sponsor  ................................ ................................ .............  32 
6.3.4.  Breaking  the Blind  ................................ ................................ .....................  33 
6.4. Study  Intervention  Compliance  ................................ ................................ ..............  33 
6.5. Concomitant Therapy  ................................ ................................ .............................  33 
6.5.1.  Prohibited Nonstudy  Vaccines and Medications During the Study  ...........  33 
6.5.2.  Permitted Nonstudy  Vaccines and Medications During the Study  ............  33 
6.5.3.  Recording  Nonstudy  Vaccinations  and Concomitant  Medications  ............  34 
6.6. Dose  Modification  ................................ ................................ ................................ .. 34 
6.7. Intervention  After  the End of the Study  ................................ ................................ . 34 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT  
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........  34 
7.1. Discontinuation of Study  Intervention  ................................ ................................ .... 34 
7.2. Participant Discontinuation/Withdrawal From the Study  ................................ ...... 34 
7.2.1.  Withdrawal  of Consent  ................................ ................................ ..............  35 
7.3. Lost to Follow -up ................................ ................................ ................................ ... 36 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ..............................  36 
8.1. Efficacy  and/or Immunogenicity  Assessments  ................................ .......................  37 
8.1.1.  GBS Vaccine Antibody  Testing  ................................ ................................ . 37 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  6  
 8.1.2.  Tdap Antibody  Testing  ................................ ................................ ...............  37 
8.1.3.  Biological Samples  ................................ ................................ .....................  38 
8.2. Safety  Assessments  ................................ ................................ ................................ .. 38 
8.2.1.  Participant  E-Diary  ................................ ................................ .....................  38 
8.2.2.  Grading Scale for Prompted Events  ................................ ............................  39 
8.2.2.1.  Local  Reactions  ................................ ................................ .........  39 
8.2.2.2.  Systemic  Events  ................................ ................................ .........  40 
8.2.2.3.  Fever  ................................ ................................ ..........................  41 
8.2.3.  Use of Antipyretic/Pain  Medication  ................................ ............................  42 
8.2.4.  Clinical  Safety  Laboratory  Assessments  ................................ .....................  42 
8.2.5.  Pregnancy  Testing  ................................ ................................ .......................  42 
8.3. Adverse  Events  and Serious  Adverse  Events  ................................ ..........................  42 
8.3.1.  Time Period and Frequency  for Collecting AE and SAE Information  ....... 43 
8.3.1.1.  Reporting SAEs to Pfizer Safety  ................................ ...............  43 
8.3.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF ...................  43 
8.3.2.  Method  of Detecting  AEs and SAEs  ................................ ...........................  44 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ ....... 44 
8.3.4.  Regulatory  Reporting Requirements for SAEs  ................................ ...........  44 
8.3.5.  Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure  ................................ .....................  45 
8.3.5.1.  Exposure During Pregnancy  ................................ ......................  45 
8.3.5.2.  Exposure  During  Breastfeeding  ................................ .................  46 
8.3.5.3.  Occupational Exposure  ................................ ..............................  47 
8.3.6.  Cardiovascular  and Death  Events  ................................ ................................  47 
8.3.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not 
Qualifying  as AEs or SAEs  ................................ ................................ ..............  47 
8.3.8.  Adverse  Events  of Special  Interest  ................................ .............................  47 
8.3.8.1.  Lack of Efficacy  ................................ ................................ ........  47 
8.3.9.  Medical  Device  Deficiencies  ................................ ................................ ...... 47 
8.3.10.  Medication  Errors  ................................ ................................ ......................  48 
8.4. Treatment of Overdose  ................................ ................................ ............................  49 
8.5. Pharmacokinetics  ................................ ................................ ................................ ..... 49 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  7  
 8.6. Pharmacodynamics  ................................ ................................ ................................ . 49 
8.7. Genetics  ................................ ................................ ................................ ..................  49 
8.8. Biomarkers  ................................ ................................ ................................ ..............  49 
8.9. Immunogenicity  Assessments  ................................ ................................ ................  49 
8.10. Health  Economics  ................................ ................................ ................................ . 49 
8.11. Study  Procedures  ................................ ................................ ................................ .. 50 
8.11.1.  Visit  1 – Vaccination  (Day  1) ................................ ................................ .. 50 
8.11.2.  Visit  2 – 1-Month  Follow -up Visit  (28-38 Days  After  Visit  1) ...............  52 
8.11.3.  Visit  3 – 6-Month  Telephone  Call Follow -up Visit  (160-200 Days  
After  Visit  1) ................................ ................................ ................................ ... 52 
8.11.4.  Unscheduled Visits  ................................ ................................ ..................  52 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ ................  54 
9.1. Estimands  and Statistical  Hypotheses  ................................ ................................ .... 54 
9.1.1.  Statistical Hypotheses  ................................ ................................ ................  54 
9.1.2.  Estimands  ................................ ................................ ................................ ... 54 
9.2. Sample Size Determination  ................................ ................................ ....................  56 
9.3. Analysis  Sets ................................ ................................ ................................ ...........  57 
9.4. Statistical Analyses  ................................ ................................ ................................ . 57 
9.4.1.  Safety  Analyses  ................................ ................................ ..........................  57 
9.4.2.  Immunogenicity  Analyses  ................................ ................................ ..........  58 
9.5. Interim  Analyses  ................................ ................................ ................................ ..... 61 
9.6. Data  Monitoring Committee or Other Independent Oversight Committee  ............  61 
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS ................................ ................................ ................................ ..........  62 
10.1. Appendix  1: Regulatory,  Ethical, and  Study  Oversight Considerations  ...............  62 
10.1.1.  Regulatory  and Ethical Considerations  ................................ ....................  62 
10.1.1.1.  Reporting of Safety Issues and Serious Breaches of the  
Protocol  or ICH GCP  ................................ ................................ ........  62 
10.1.2.  Financial  Disclosure  ................................ ................................ .................  63 
10.1.3.  Informed  Consent  Process  ................................ ................................ ....... 63 
10.1.4.  Data  Protection  ................................ ................................ .........................  64 
10.1.5.  Dissemination  of Clinical Study  Data ................................ ......................  64 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  8  
 10.1.6.  Data  Quality  Assurance  ................................ ................................ ............  65 
10.1.7.  Source Documents  ................................ ................................ ...................  66 
10.1.8.  Study  and Site Start and Closure  ................................ ..............................  67 
10.1.9.  Publication Policy  ................................ ................................ ....................  68 
10.1.10.  Sponsor’s  Qualified  Medical  Personnel  ................................ .................  69 
10.2. Appendix 2:  Clinical  Laboratory  Tests  ................................ ................................  69 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording,  
Evaluating,  Follow -up, and Reporting  ................................ ................................ ...... 70 
10.3.1.  Definition  of AE ................................ ................................ .......................  70 
10.3.2.  Definition  of an SAE ................................ ................................ ................  71 
10.3.3.  Definition of Medically  Attended Adverse Event  ................................ ... 72 
10.3.4.  Definition  of Immediate  Adverse  Event  ................................ ..................  73 
10.3.5.  Recording/Reporting  and Follow -up of AEs and/or  SAEs  ......................  73 
10.3.6.  Reporting  of SAEs  ................................ ................................ ...................  76 
10.4. Appendix  4: Contraceptive  Guidance  ................................ ................................ ... 78 
10.4.1.  Female Participant Reproductive Inclusion Criteria  ................................  78 
10.4.2.  Woman  of Childbearing  Potential  ................................ ............................  78 
10.4.3.  Contraception  Methods  ................................ ................................ ............  79 
10.5. Appendix  5: Liver  Safety:  Suggested  Actions  and Follow -up Assessments  ........  81 
10.6. Appendix 6: Protocol Amendment History  ................................ ..........................  83 
10.7. Appendix 7: Abbreviations  ................................ ................................ ...................  87 
11. REFERENCES  ................................ ................................ ................................ ..................  90 
 
LIST OF TABLES  
Table  1. Local Reaction Grading Scale  ................................ ................................ . 40 
Table  2. Systemic  Event  Grading Scale  ................................ ................................ . 41 
Table  3. Ranges  for Fever  ................................ ................................ ......................  42 
Table  4. Probability  of Observing at  Least 1  Event  by Assumed  True Event  
Rates  ................................ ................................ ................................ ..........  57 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  9  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis 
Rationale  
Pfizer is developing a group B streptococcus 6 -valent polysaccharide conjugate vaccine 
(GBS6)  for the prevention  of group  B streptococcal  invasive  disease  due to the 6 serotypes 
that cause the majority of disease in infants (serotypes Ia, Ib, II, III, IV, and V) by active 
immunization of pregnant women.  Pregnant women have been vaccinated globally to 
prevent neonatal tetanus and pertussis in young infants, and to protect women and their 
infants against influenza.  
Tetanus - and pertussis -containing vaccines are recommended in many countries during 
pregnancy.  In the US, tetanus, diphtheria, and acellular pertussis vaccine (Tdap) is 
recommended for administration between 27 and 36 weeks of gestation.  As GBS6 is being 
evaluated  for administration  within  the same  gestational  timeframe,  information  on the safety 
and potential immune interference of concomitantly administered Tdap and GBS6 is 
important to understand prior to GBS6 licensure.  
Study C1091005 is a descriptive study that will evaluate the concomitant administration of 
GBS6  and Tdap  among  nonpregnant  women  to rule out significant  interference.  The study  is 
expected to provide useful data prior to the Phase 3 definitive coadministration assessment 
program in pregnant women.  
Objectives,  Estimands,  and Endpoints  
 
Objectives  Estimands  Endpoints  
Primary  (Safety):  Primary  (Safety):  Primary  (Safety):  
• To describe  the 
safety and 
tolerability of 
GBS6 when 
administered 
concomitantly 
with Tdap 
(GBS6+Tdap)  
and when GBS6 
is administered 
alone 
(GBS6+placebo).  In participants  receiving  at least 1 dose of the 
investigational products:  
• The proportion  of participants  reporting 
prompted local reactions within 7 days 
following investigational product 
administration.  
• The proportion  of participants  reporting 
prompted  systemic  events  within  7 days 
following investigational product 
administration.  
• The proportion  of participants  reporting 
adverse events (AEs) through 1 month 
following investigational product 
administration.  
• The proportion  of participants  reporting 
medically attended adverse events 
(MAEs) and serious adverse events 
(SAEs) through 6 months following 
investigational product administration.  • Prompted  local  reactions  (redness,  swelling, 
and pain at the injection site).  
• Prompted systemic events (fever, 
nausea/vomiting,  diarrhea,  headache,  fatigue, 
muscle pain, and joint pain).  
• AEs.  
• MAEs  and SAEs.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  10  
  
Objectives  Estimands  Endpoints  
Primary 
(Immunogenicity):  Primary  (Immunogenicity):  Primary  (Immunogenicity):  
• To describe the 
immune 
responses 
induced  by Tdap 
when 
administered 
concomitantly 
with GBS6 
(GBS6+Tdap)  
compared to the 
immune 
responses 
induced  by Tdap 
(placebo+Tdap) 
alone.  In participants receiving all doses of the 
investigational  products  and in compliance 
with the key protocol criteria (evaluable 
participants):  
• The difference in proportions of 
participants with anti –tetanus toxoid 
antibody concentrations ≥0.1 IU/mL 
measured 1 month after vaccination 
between  the GBS6+Tdap  group  and the 
placebo+Tdap group.  
• The difference in proportions of 
participants  with anti–diphtheria  toxoid 
antibody concentrations ≥0.1 IU/mL 
measured 1 month after vaccination 
between  the GBS6+Tdap  group  and the 
placebo+Tdap group.  
• Geometric mean ratio (GMR), estimated 
by the GMR of anti –pertussis toxin 
antibodies  from  the GBS6+Tdap  group  to 
the placebo+Tdap group measured  
1 month  after vaccination.  
• GMR,  estimated  by the GMR  of 
anti–filamentous  hemagglutinin 
(anti-FHA) antibodies from the  
GBS6+Tdap  group  to the placebo+Tdap 
group measured 1 month after 
vaccination.  
• GMR, estimated by the GMR of 
antipertactin  (anti-PRN)  antibodies  from 
the GBS6+Tdap group to the 
placebo+Tdap group measured 1 month 
after vaccination.  • Anti–tetanus toxoid and anti –diphtheria 
toxoid antibodies and anti –pertussis 
component  (pertussis  toxin,  FHA,  and PRN) 
antibodies.  
• To describe  the 
immune 
responses 
induced by 
GBS6 when 
administered 
concomitantly 
with Tdap 
(GBS6+Tdap)  
compared  to the 
immune 
responses 
induced by 
GBS6  
(GBS6+placebo) 
alone.  • GBS capsular polysaccharide (CPS) 
serotype -specific  IgG GMR,  estimated  by 
the GMR of GBS CPS serotype -specific 
IgG antibodies from the GBS6+Tdap 
group to the GBS6+placebo group 
measured 1 month after vaccination.  • GBS  CPS serotype -specific  IgG antibody 
concentrations.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  11  
  
Objectives  Estimands  Endpoints  
Secondary:  Secondary:  Secondary:  
• N/A • N/A • N/A 
Exploratory 
(Immunogenicity):  Exploratory  (Immunogenicity):  Exploratory  (Immunogenicity):  
• To further 
describe the 
immune 
responses 
elicited  by Tdap 
when 
administered 
concomitantly 
with GBS6 
(GBS6+Tdap)  
compared to 
Tdap 
(placebo+Tdap) 
alone.  In participants receiving all doses of the 
investigational  products  and in compliance 
with the key protocol criteria (evaluable 
participants):  
• Proportions  of participants  with 
anti–tetanus toxoid and  
anti–diphtheria toxoid antibody 
concentrations  ≥0.1 IU/mL  measured 
before  vaccination  and 1 month  after 
vaccination  for both the GBS6+Tdap 
group and the placebo+Tdap group.  
• Proportions  of participants  with 
anti–tetanus toxoid and  
anti–diphtheria toxoid antibody 
concentrations  ≥1.0 IU/mL  measured 
before  vaccination  and 1 month  after 
vaccination  for both the GBS6+Tdap 
group and the placebo+Tdap group.  
• The differences in proportions of 
participants  with anti–tetanus  toxoid  and 
anti–diphtheria toxoid antibody 
concentrations ≥1.0 IU/mL measured at 
1 month after vaccination between the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• GMCs  of anti–tetanus  toxoid, 
anti–diphtheria toxoid, and  
anti–pertussis component (pertussis 
toxin,  FHA,  PRN,  and FIM)  antibodies 
measured before vaccination and  
1 month  after vaccination  for both the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• Geometric mean fold rise (GMFRs) of 
anti–tetanus toxoid, anti -diphtheria 
toxoid, and anti –pertussis component 
(pertussis toxin, FHA, PRN, and FIM) 
antibodies measured from before 
vaccination  to 1 month  after vaccination 
for both the GBS6+Tdap group and the 
placebo+Tdap group.  • Anti–tetanus toxoid, anti –diphtheria toxoid, 
and anti–pertussis  component  (pertussis  toxin, 
FHA, PRN, and FIM) antibody  
concentrations.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  12  
  
Objectives  Estimands  Endpoints  
• To further 
describe the 
immune 
responses  
elicited  by GBS6 
when 
administered 
concomitantly 
with Tdap 
(GBS6+Tdap)  
compared  to 
GBS6  
(GBS6+placebo) 
alone.  • GBS  CPS serotype -specific  IgG GMCs 
measured before and 1 month after 
vaccination for both the GBS6+Tdap 
group and the GBS6+placebo group.  
• GBS  CPS serotype -specific  IgG GMFRs 
measured from before vaccination to  
1 month  after vaccination  for both the 
GBS6+Tdap group and the 
GBS6+placebo group.  • GBS  CPS serotype -specific  IgG antibody 
concentrations.  
 
Overall  Design  
This is a Phase 2, multicenter, placebo -controlled, randomized, observer -blinded study in 
which approximately 300 healthy nonpregnant women, 18 through 49 years of age, will be 
randomized  to evaluate  concomitant  administration  of GBS6  and Tdap.  Participants  will be 
randomized in a 1:1:1 ratio to receive 20 µg GBS6 and concomitant Tdap (GBS6+Tdap),  
20 µg GBS6 and placebo (GBS6+placebo), or Tdap and placebo (placebo+Tdap).  
Participants will have blood drawn prior to vaccination (Visit 1) and at 1 month after 
vaccination (Visit 2).  Electronic diaries (e -diaries) will be used to collect prompted local 
reaction  and systemic  event  data for 7 days after vaccination  (Days  1 through  7, where  Day 1 
is the day of vaccination).  AEs will be collected through Visit 2.  MAEs and SAEs will be 
collected through Visit 3.  
An external data  monitoring committee  (E-DMC)  will be utilized.  
Number of Participants  
Approximately  300 participants  will be randomly  assigned  to the investigational  products  to 
achieve a target of 270 evaluable participants, assuming 10% nonevaluability.  
Intervention  Groups  and Duration  
Participants will be enrolled and randomized in a 1:1:1 ratio to receive 1 of the 
following  3 groups:  GBS6+Tdap,  GBS6+placebo,  or placebo+Tdap,  to achieve  a target 
of 270 evaluable participants, assuming 10% nonevaluability.  Details of sample size 
determination can be found in Section 9.2 . 
Participants  will take part in the study  from  enrollment  to approximately  6 months  after 
vaccination.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  13  
 Data  Monitoring  Committee  
This study will use an established E -DMC.  The E -DMC is independent of the study team 
and includes  only external  members.  The E-DMC  charter  describes  the role of the E-DMC 
in more detail.  
The E -DMC will be responsible for ongoing monitoring of the safety of participants in the 
study according to the charter.  The recommendations made by the E -DMC to alter the 
conduct  of the study  will be forwarded  to the appropriate  Pfizer  personnel  for final decision. 
Pfizer will forward such decisions, which may include summaries of aggregate analyses of 
safety data, to regulatory authorities, as appropriate.  
Statistical  Methods  
The statistical  data analysis  of the study  results  will be descriptive  in nature.  An estimation 
approach will be used to assess the safety and immunogenicity objectives in the study.  
Summary  statistics  will be provided  for all binary  and continuous  endpoints  related  to study 
primary and exploratory objectives.  
The statistical analysis plan (SAP) will be developed and finalized before database lock and 
will describe  the participant  populations  to be included  in the analyses  and the procedures  for 
accounting for missing, unused, and spurious data.  A summary of the planned statistical 
analyses of the primary and secondary endpoints can be found in Section 9 . 
1.2. Schema  
Not applicable.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  14  
  
1.3. Schedule of Activities  
The SoA table provides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND  
PROCEDURES  section  of the protocol  for detailed  information  on each procedure  and assessment  required  for compliance  with the 
protocol.  
The investigator  may schedule  visits  (unplanned  visits)  in addition  to those  listed  in the SoA table,  in order  to conduct  evaluations  or 
assessments required to protect the well -being of the participant.  
 
Visit  Number  1 2 3 
Visit  Description  Vaccination  1-Month  Follow -up Visit  6-Month  Follow -up Call 
Visit  Window  (Days)a Day 1 28-38 Days  After  Visit  1 160-200 Days  After  Visit  1 
Type  of Visit  Clinic  Clinic  Phone  Call 
Obtain  informed  consent  X   
Assign  a participant  number  using  the IRT system  X   
Record  demography,  medical  history,  physical  examination,  vital 
signsb X   
Perform  urine  pregnancy  test X   
Record  nonstudy  vaccine  information  X X X 
Record  medication  information  X Xc Xc 
Review  inclusion  and exclusion  criteria  X   
Measure  prevaccination  oral temperature  X   
Contraception  checkd X X  
Review  temporary  delay  criteria  X   
Review  continued  eligibility   X X 
Assign  randomization  and container  number  X   
Obtain  blood  draw  for immunogenicity  assessmente X 
(~50 mL) X 
(~50 mL)  
Administer  investigational  products  X   
Postvaccination  observation  (at least 30 minutes)  and assessment  of 
immediate AEs  X   
Issue/activate  e-diary  devicef X   
Issue  thermometer  and measuring  device  X   
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  15  
  
Visit  Number  1 2 3 
Visit  Description  Vaccination  1-Month  Follow -up Visit  6-Month  Follow -up Call 
Visit  Window  (Days)a Day 1 28-38 Days  After  Visit  1 160-200 Days  After  Visit  1 
Type  of Visit  Clinic  Clinic  Phone  Call 
Provide  the participant  with a contact  card X   
Review  and/or  collect  e-diaryg  X  
Record  AEs X X  
Record  MAEs  and SAEs  X X X 
Abbreviations:  AE = adverse  event;  IRT = interactive  response  technology;  GBS  = group  B streptococcus;  MAE  = medically  attended  event;  SAE  = serious 
adverse event.  
a. Day relative  to start of study  vaccination  (Day  1). 
b. Vital  signs  include  weight,  height,  sitting  blood  pressure  and pulse  rate, respiratory  rate, and temperature  (oral).  
c. Only  concomitant  medications  taken  to treat an AE, MAE,  or SAE  will be recorded  in the case report  form,  as appropriate.  
d. The contraception  check  is an opportunity  to confirm  that contraception  is used consistently  and correctly  through  the required  time period  per protocol 
(28 days after vaccination).  
e. All blood  volumes  are approximate  and at Visit  1 will be taken  prior  to vaccination.  
f. Participants  will record  prompted  reactogenicity  events  in an e-diary  each evening  for 7 days following  vaccination  (where  Day 1 is the day of vaccination). 
Remind participants that study staff may contact them to obtain additional information on Grade 3 events entered into the e -diary.  Ask participants to 
contact the investigator or site staff immediately if they are prompted by the e -diary from Day 1 through Day 7 following vaccination to determine if an 
unscheduled visit is required to assess a Grade 4 event.  
g. Designated  site staff will review  e-diary  data online  following  vaccination  to evaluate  participant  compliance  and as part of the ongoing  safety  review.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  16  
 2. INTRODUCTION  
GBS6  is being  developed  for: 
• Active  immunization  to prevent  disease  caused  by GBS  serotypes  (Ia, Ib,  II, III, IV, and 
V) contained in the vaccine.  
2.1. Study Rationale  
GBS6  is being  developed  to address  the global  unmet  medical  need  for prevention  of infant 
GBS disease.  It is based on the well -established platform of vaccines composed of CPSs 
conjugated to the CRM 197 protein that target the polysaccharide capsules of encapsulated 
bacteria.  Maternal immunization with an efficacious GBS vaccine would likely offer 
benefits beyond existing approaches to prevent infant GBS disease.  The vaccine may also 
protect against adverse fetal outcomes by reducing GBS colonization in pregnant women. 
Pregnant women may also benefit directly from a GBS vaccine by the prevention of 
peripartum GBS disease.  Other populations, such as adults of advanced age or with 
particular GBS risk factors, may be considered for GBS6 vaccine evaluation in the future.  
Pregnant  women  are vaccinated  globally  to prevent  neonatal  tetanus  and pertussis  in young 
infants, and to protect women and their infants against influenza.  
Tetanus - and pertussis -containing vaccines are recommended in many countries during 
pregnancy.  In the US, tetanus, diphtheria, and acellular pertussis vaccine (Tdap) is 
recommended  for administration  between  27 and 36 weeks’  gestation  of each pregnancy.  As 
GBS6 is being evaluated for administration within the same timeframe, information on the 
safety and potential immune interference of Tdap and GBS6 administered concomitantly are 
important to understand prior to evaluation of GBS6 in late -stage clinical trials and before 
GBS6 licensure.  
Study C1091005 is a descriptive study that will evaluate the concomitant administration of 
GBS6  and Tdap  among  nonpregnant  women  to rule out significant  interference.  The study  is 
expected  to provide  data prior  to the Phase  3 definitive  coadministration  assessment  program 
in pregnant women.  
2.2. Background  
2.2.1.  Disease  Overview  
Streptococcus  agalactiae , also known  as GBS,  is an encapsulated,  gram -positive  coccus  that 
is associated with lower intestinal and rectovaginal colonization.  There are 10 serotypes of 
GBS (Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX) differentiated by the composition of their 
polysaccharide capsule.  Although all GBS serotypes have been found to cause disease, 6 
serotypes  (Ia, Ib, II, III, IV, and V) have  been  found  to cause  >95%  of disease  globally,  with 
variability in their global prevalence and virulence.1,2 GBS disease most frequently occurs 
in the very young —newborns and infants younger than 3 months of age —and the elderly, 
especially older adults with comorbid conditions.3,4,5,6,7 However, GBS disease has been 
reported in individuals of all ages, and pregnant women may be particularly susceptible.8 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  17  
 Among infants, GBS may cause serious disease, including sepsis, meningitis, and 
pneumonia; less common manifestations include skin and soft tissue, bone, and joint 
infections.9 In pregnant women, GBS may be associated with ascending infections ranging 
from relatively benign urinary tract infections to chorioamnionitis (which may result in 
stillbirth or preterm delivery) and puerperal sepsis (which may be fatal).10 Bacteremia 
without  a focus,  cellulitis,  bone  and joint infections,  and urinary  tract infections  are common 
disease manifestations of GBS infection in older nonpregnant adults.6,11,12 
2.2.2.  Maternal  Immunization  as an Approach  to Prevent  Disease  in Infants  and 
Pregnant Women  
The goal of maternal immunization is to generate protective antibodies that may be 
placentally transferred in utero to provide the newborn and young infant with IgG antibody 
concentrations at birth sufficient to protect them against infections during the period of 
increased vulnerability until they are able to adequately respond to their own active 
immunizations or infectious challenges.  Examples of this concept include vaccination with 
tetanus,  pertussis,  or influenza  vaccines  to provide  maternally  transferred  antibody  protection 
against the cognate pathogen.  Pfizer is following this paradigm to develop vaccines for 
respiratory syncytial virus (RSV) and GBS infections.13 
Vaccination of pregnant women is used globally in the prevention of neonatal tetanus and 
pertussis  in young  infants,  and to protect  women  and their infants  against  influenza.14,15,16,17,18 
There is increasing experience with the safety, effectiveness, and acceptance of influenza 
vaccine and tetanus toxoid – and pertussis -containing vaccines for use in pregnant women in 
various regions globally to prevent disease in newborns and infants.17,19,20 Maternal 
immunization against influenza is recommended by the US Advisory Committee on 
Immunization Practices (ACIP).21 In addition, several countries recommend maternal Tdap 
vaccination during every pregnancy, including closely spaced pregnancies.  To date, these 
vaccines have demonstrated an acceptable safety profile with single and repeat dosing.22,23,24 
Current preventive measures against invasive GBS disease in infants vary by region and 
include universal screening of pregnant women in the third trimester of pregnancy and 
administration of intrapartum antibiotic prophylaxis (IAP) to prevent disease in the infant, a 
risk-based  approach  to IAP, or no prevention  intervention.7,9,25 Each  of these  approaches  has 
limitations, and while implementation of IAP policies has reduced incidence of early -onset 
disease (EOD), there has not been a measurable impact on late -onset disease (LOD; beyond 
the first week of life) and a significant EOD burden remains.  Published data from natural 
history studies have demonstrated a general correlation between maternal GBS antibody 
levels and a reduced risk of GBS disease in newborns, with an attempt made to derive an 
immunological threshold of protection.26,27,28,29,30 These studies established clearly that 
antibodies to GBS capsular polysaccharides in the mother correlated with protection against 
GBS  disease  in the infant.  Immunization  of pregnant  women  with a GBS  vaccine,  therefore, 
is a reasonable alternative approach to prevent invasive GBS disease in young infants and 
possibly GBS disease in pregnant or postpartum women.31 A licensed GBS vaccine 
approved for administration in pregnancy would likely be given in the second trimester 
and/or during the third trimester.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  18  
 There  is currently  no licensed  vaccine  for the prevention  of GBS  disease;  however,  Pfizer  is 
developing a multivalent vaccine for the prevention of invasive GBS disease in infants.  
GBS6 was evaluated in a Phase 1/2 first -in-human (FIH) study in healthy nonpregnant 
women and men 18 through 49 years of age in the US.  GBS6 was safe and well -tolerated 
and elicited  robust  immune  responses  that persisted  through  6 months  after vaccination  at all 
dose levels and formulations.  No meaningful difference in the GBS CPS IgG immune 
responses were observed for any serotype between GBS6 doses or formulations.  No safety 
risks were identified beyond reactogenicity  through 6 months.  The safety  findings  from  this 
FIH study are similar to those of other investigational GBS vaccines and of other licensed 
vaccines recommended for use in pregnancy.32,33,34,35 
The purpose  of this Phase  2b descriptive  study  is to evaluate  the concomitant  administration 
of GBS6 and Tdap.  The study is expected to provide data prior to the Phase 3 definitive 
coadministration assessment program in pregnant women, which will inform future studies 
with pregnant women in which Tdap may be used.  
2.3. Benefit/Risk  Assessment  
Pfizer  is developing  GBS6  to address  a global  unmet  medical  need  for the prevention  of GBS 
disease due to 6 serotypes in young infants by active immunization of pregnant women.  
GBS6 is composed of polysaccharides of the 6 most prevalent serotypes causing >95% of 
GBS disease in infants and adults,1,4 individually conjugated to the CRM 197 carrier protein. 
An efficacious vaccine would offer a favorable adjunct option to currently existing 
approaches  for GBS  disease  prevention  by providing  greater  feasibility  of implementation  in 
low- and middle -income countries (LMICs), and the potential to provide protection against 
disease, including both EOD and LOD, in infants.  In addition, there is a long history of 
success  in protecting  pediatric  and adult  populations  against  diseases  caused  by encapsulated 
bacteria using vaccines that target CPSs and generate functional antibodies that eliminate 
bacteria by opsonophagocytosis.  
A completed  Phase  1/2 study  of GBS6  in healthy  adults  demonstrated  that GBS6  was safe 
and well -tolerated in healthy nonpregnant women and healthy men and elicited robust 
immune responses that persisted through 6 months after vaccination at all dose levels and 
formulations evaluated.  The study's safety findings were similar to those of other 
investigational GBS and licensed vaccines recommended for use in pregnancy.  The data 
provide support for continuing evaluation of GBS6 in later -phase trials and in pregnant 
women.  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of GBS6  may be found  in the GBS6  investigator’s  brochure  (IB),  which  is the 
SRSD for this study.  
The SRSD  for Tdap  will be the product  information  for the US, where  this vaccine  will be 
procured.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  19  
  
2.3.1.  Risk  Assessment  
 
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention(s)  – GBS6,  Tdap,  and Placebo  
Potential  risks  associated  with GBS6  in the age 
group for this study include the following:  
• Injection  site redness  
• Injection  site swelling  
• Injection  site pain or tenderness  
• Fever  
As with any vaccine,  a rare but possible  event 
associated with GBS6 is:  
• Hypersensitivity reaction, including 
swelling of the face or lips (face edema), 
wheezing  (bronchospasm),  or difficulty  in 
breathing (dyspnea)  The potential risks are based on the FIH 
C1091001  study  results  and those  described  in 
the IB.  Eligibility  criteria  have  been  selected  to ensure 
that only appropriate healthy participants are 
included in the study (see Section 5 ). 
 
Individuals with significant reactions after 
vaccination  or AEs considered  by the investigator 
to present  increased  risk to the participant  or who 
develop exclusionary conditions during the 
conduct of the study will be excluded from 
interventions but may be followed for safety.  
Potential  risks  associated  with Tdap  in the age group 
for this study include the following:  
• Injection  site pain 
• Injection  site swelling  
• Injection  site redness  
• Headache  
• Body  ache or muscle  weakness  The risks  are based  on the known  safety  profile 
of a commonly used Tdap in this age group, 
presented in the Adacel USPI.  Eligibility  criteria  have  been  selected  to ensure 
that only appropriate healthy participants are 
included in the study (see Section 5 ). 
Individuals with significant reactions after 
vaccination  or AEs considered  by the investigator 
to present  increased  risk to the participant  or who 
develop exclusionary conditions during the 
conduct of the study will be excluded from 
interventions but may be followed for safety.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  20  
  
Potential  Risk  of Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention(s)  – GBS6,  Tdap,  and Placebo  
Potential  risks  associated  with placebo  in the age 
group for this study include the following:  
• Injection  site pain 
• Injection  site swelling  
• Injection  site redness  The risks  are based  on commonly  observed 
events in vaccine studies using a placebo.  Eligibility  criteria  have  been  selected  to ensure 
that only appropriate healthy participants are 
included in the study (see Section 5 ). 
Individuals with significant reactions after 
vaccination  or AEs considered  by the investigator 
to present  increased  risk to the participant  or who 
develop exclusionary conditions during the 
conduct of the study will be excluded from 
interventions but may be followed for safety.  
Study  Procedures  – Venipuncture  
Venipuncture  will be performed  during  the study.  There is a risk of bleeding, bruising, hematoma 
formation,  and infection  at the venipuncture  site 
and an overall risk of dizziness and fainting 
associated with the procedure.  Only qualified nurses, physicians, nurse 
practitioners,  physician’s  assistants,  phlebotomists, 
or medical assistants certified or otherwise 
authorized to draw blood per the standards and 
procedures of the investigative site as allowed by 
institutional, local, and state guidance will be 
allowed to draw blood to minimize local 
complications.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  21  
 2.3.2.  Benefit  Assessment  
GBS6  is being  developed  to benefit  infants  through  the vaccination  of pregnant  women.  The 
current study will provide important information about interference of GBS6 and Tdap in 
nonpregnant women to inform future studies in pregnant women.  Nonpregnant women may 
benefit from participation in this study  from the development of GBS antibodies, which may 
protect them from GBS disease in the near future.  
Other benefits to the individual participant may include receipt of a booster Tdap and 
protection from Tdap -associated disease, physical examination by a medical provider at the 
start of the study and prior to each study vaccination, a thorough review of the participant’s 
vaccination  status,  and evaluation  and management  of some  illnesses  (AEs)  that occur  during 
participation in the study as part of protocol -specified scheduled and unscheduled 
assessments.  
2.3.3.  Overall Benefit/Risk Conclusion  
The anticipated benefit (protective immunity against GBS6) that may be afforded to 
participants outweighs the potential risks in this study, including the possibility of transient 
local  and systemic  reactogenicity  events  of varying  severity  and possible  complications  from 
needlesticks (vaccination or venipuncture) for an overall favorable benefit/risk assessment.  
3. OBJECTIVES,  ESTIMANDS,  AND  ENDPOINTS  
 
Objectives  Estimands  Endpoints  
Primary  (Safety):  Primary  (Safety):  Primary  (Safety):  
• To describe the safety and 
tolerability of GBS6 when 
administered  concomitantly  with 
Tdap (GBS6+Tdap) and when 
GBS6 is administered alone 
(GBS6+placebo).  In participants  receiving  at least 1 dose 
of the investigational products:  
• The proportion of participants 
reporting  prompted  local  reactions 
within 7 days following 
investigational product 
administration.  • Prompted  local  reactions  (redness, 
swelling, and pain at the injection 
site).  
• Prompted  systemic  events  
(fever,  nausea/vomiting,  diarrhea, 
headache, fatigue, muscle pain, 
and joint pain).  
 • The proportion of participants 
reporting  prompted  systemic  events 
within 7 days following 
investigational product 
administration.  • AEs.  
• MAEs  and SAEs.  
 • The proportion of participants 
reporting  adverse  events  (AEs) 
through 1 month following 
investigational product 
administration.   
 • The proportion of participants 
reporting medically attended 
adverse  events  (MAEs)  and serious 
adverse events (SAEs) through  
6 months  following  investigational 
product administration.   
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  22  
  
Objectives  Estimands  Endpoints  
Primary  (Immunogenicity):  Primary  (Immunogenicity):  Primary  (Immunogenicity):  
• To describe  the immune  responses 
induced by Tdap when 
administered concomitantly with 
GBS6  (GBS6+Tdap)  compared  to 
the immune responses induced by 
Tdap (placebo+Tdap) alone.  In participants  receiving  all doses  of 
the investigational products and in 
compliance with the key protocol 
criteria (evaluable participants):  
• The difference  in proportions  of 
participants with anti –tetanus 
toxoid antibody concentrations  
≥0.1 IU/mL  measured  1 month 
after vaccination between the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• The difference  in proportions  of 
participants  with anti–diphtheria 
toxoid antibody concentrations  
≥0.1 IU/mL  measured  1 month 
after vaccination between the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• Geometric  mean  ratio (GMR), 
estimated by the GMR of 
anti–pertussis  toxin  antibodies  
from  the GBS6+Tdap  group  to the 
placebo+Tdap group measured  
1 month  after vaccination.  
• GMR,  estimated  by the GMR  of 
anti–filamentous  hemagglutinin 
(anti-FHA) antibodies from the 
GBS6+Tdap group to the 
placebo+Tdap group measured  
1 month after vaccination.  
• GMR, estimated by the GMR of 
antipertactin (anti -PRN) 
antibodies from the GBS6+Tdap 
group  to the placebo+Tdap  group 
measured 1 month after 
vaccination.  • Anti–tetanus toxoid and anti – 
diphtheria  toxoid  antibodies  and 
anti–pertussis component 
(pertussis  toxin,  FHA,  and PRN) 
antibodies.  
• To describe  the immune  responses 
induced by GBS6 when 
administered concomitantly with 
Tdap (GBS6+Tdap) compared to 
the immune responses induced by 
GBS6 (GBS6+placebo) alone.  • GBS capsular polysaccharide 
(CPS) serotype -specific IgG 
GMR,  estimated  by the GMR  of 
GBS CPS serotype -specific IgG 
antibodies  from  the GBS6+Tdap 
group to the GBS6+placebo 
group measured 1 month after 
vaccination.  • GBS  CPS serotype -specific  IgG 
antibody concentration.  
Secondary:  Secondary:  Secondary:  
• N/A • N/A • N/A 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  23  
  
Objectives  Estimands  Endpoints  
Exploratory  (Immunogenicity):  Exploratory  (Immunogenicity):  Exploratory  (Immunogenicity):  
• To further describe the immune 
responses elicited by Tdap when 
administered concomitantly with 
GBS6  (GBS6+Tdap)  compared  to 
Tdap (placebo+Tdap) alone.  In participants  receiving  all doses  of 
the investigational products and in 
compliance with the key protocol 
criteria (evaluable participants):  
• Proportions  of participants  with 
anti–tetanus toxoid and  
anti–diphtheria  toxoid  antibody 
concentrations ≥0.1 IU/mL 
measured before vaccination 
and 1 month after vaccination 
for both the GBS6+Tdap  group 
and the placebo+Tdap group.  
• Proportions  of participants  with 
anti–tetanus toxoid and  
anti–diphtheria  toxoid  antibody 
concentrations ≥1.0 IU/mL 
measured before vaccination 
and 1 month after vaccination 
for both the GBS6+Tdap  group 
and the placebo+Tdap group.  
• The differences in proportions 
of participants  with anti–tetanus 
toxoid and anti –diphtheria 
toxoid antibody concentrations  
≥1.0 IU/mL  measured  1 month 
after vaccination between the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• GMCs of anti –tetanus toxoid, 
anti–diphtheria toxoid, and 
anti–pertussis component 
(pertussis toxin, FHA, PRN, 
and FIM) antibodies measured 
before  vaccination  and 1 month 
after vaccination for both the 
GBS6+Tdap group and the 
placebo+Tdap group.  
• Geometric mean fold rises 
(GMFRs) of anti –tetanus 
toxoid,  anti–diphtheria  toxoid, 
and anti –pertussis component 
(pertussis toxin, FHA, PRN, 
and FIM)  antibodies  measured 
from before vaccination to  
1 month after vaccination for 
both the GBS6+Tdap  group  and 
the placebo+Tdap group.  • Anti–tetanus  toxoid,  
anti–diphtheria toxoid, and anti –
pertussis component (pertussis  
toxin,  FHA,  PRN,  and FIM) 
antibody concentrations.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  24  
  
Objectives  Estimands  Endpoints  
• To further describe the immune 
responses  elicited  by GBS6  when 
administered concomitantly with 
Tdap  (GBS6+Tdap)  compared  to 
GBS6 (GBS6+placebo) alone.  • GBS  CPS serotype -specific  IgG 
GMCs measured before and 1 
month  after vaccination  for both 
the GBS6+Tdap group and the 
GBS6+placebo group.  
• GBS  CPS serotype -specific  IgG 
GMFRs measured from before 
vaccination to 1 month after 
vaccination for both the 
GBS6+Tdap group and the 
GBS6+placebo group.  • GBS  CPS serotype -specific  IgG 
antibody concentrations.  
 
4. STUDY  DESIGN  
4.1. Overall  Design  
This Phase  2, multicenter,  placebo -controlled,  randomized,  observer -blinded  study  will enroll 
approximately 300 healthy nonpregnant women from US investigative sites, 18 through 49 
years of age, who will be randomized to evaluate concomitant administration of GBS6 and 
Tdap.  Participants will be randomized in a 1:1:1 ratio to receive 20 µg GBS6 and 
concomitant Tdap, 20 µg GBS6 and placebo, or Tdap and placebo.  
Participants will have blood drawn prior to vaccination (Visit 1) and at 1 month after 
vaccination  (Visit  2). E-diaries  will be used to collect  prompted  local  reaction  and systemic 
event data for 7 days after vaccination (Days 1 through 7, where Day 1 is the day of 
vaccination).  AEs will be collected through Visit 2.  MAEs and SAEs will be collected 
through Visit 3.  
Participants  will take part in the study  from  enrollment  to 6 months  after vaccination. 
An E -DMC will be utilized.  
4.2. Scientific Rationale for Study Design  
Refer  to Section  2.1. 
Human reproductive safety  data are limited for GBS6.  
Based  on the pharmacology  of the compound  and data from  reproductive  toxicity  in animals, 
there  is no expectation  of human  teratogenicity.  However,  as data in humans  are limited,  the 
use of a highly effective method of contraception is required (see Appendix 4 ). 
4.3. Justification for Dose  
The dose of vaccine  that will be used in this study  was determined  following  assessment  of 
safety and immunogenicity data from the FIH study (C1091001) and Study C1091002.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  25  
 The FIH study  was conducted  in healthy  nonpregnant  women  and healthy  men in the US and 
assessed the safety and immunogenicity of 3 different dose levels of GBS6 (5, 10, or  
20 µg/serotype,  formulated  with or without  AlPO 4). GBS6  was safe and well-tolerated  and 
elicited robust immune responses at all dose levels and formulations.  The highest dose  
(20 µg/serotype, formulated without AlPO 4) is selected for this study, as this is the 
dose/formulation that has been selected for future licensure studies and has shown an 
acceptable safety profile, the greatest consistent postvaccination immune responses in 
pregnant  women,  and measurable  IgG antibody  concentrations  in infants  in Study  C1091002.  
4.4. End of Study Definition  
The end of the study  is defined  as the date of the last visit of the last participant  in the study.  
5. STUDY POPULATION  
This study can fulfill its objectives only if appropriate participants are enrolled.  The 
following  eligibility  criteria  are designed  to select  participants  for whom  participation  in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol.  
Prospective  approval  of protocol  deviations  to recruitment  and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion  Criteria  
Participants  are eligible  to be included  in the study  only if all of the following  criteria  apply:  
Age and Sex: 
1. Healthy  women  ≥18 and ≤49 years  of age. Refer  to Appendix  4 for reproductive  criteria 
for female participants ( Section 10.4.1 ). 
Type  of Participant  and Disease Characteristics:  
2. Participants  who are willing  and able to comply  with scheduled  visits,  investigational 
plan, laboratory tests, lifestyle considerations, and other study procedures, including 
completion of the e -diary from Day 1 to Day 7 following administration of 
investigational product.  
3. Healthy females at enrollment who are determined by medical history, physical 
examination,  and clinical  judgment  of the investigator  to be eligible  for inclusion  in the 
study.  
4. Expected  to be available  for the duration  of the study  and who can be contacted  by 
telephone during study participation.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  26  
 Informed  Consent:  
5. Capable  of giving  personal  signed  informed  consent  as described  in Appendix  1, which 
includes  compliance  with the requirements  and restrictions  listed  in the ICD and in this 
protocol.  
5.2. Exclusion  Criteria  
Participants  are excluded  from the  study  if any of the  following  criteria apply:  
1. Pregnant  female  participants;  breastfeeding  female  participants;  positive  urine  pregnancy 
test for women of childbearing potential (WOCBP) at Visit 1 (prior to vaccination); and 
WOCBP who are, in the opinion of the investigator, sexually active and at risk for 
pregnancy; and WOCBP who are unwilling or unable to use effective methods of 
contraception as outlined in this protocol from the signing of the informed consent until 
at least 28 days after the last dose of investigational product.  
Medical Conditions:  
2. History  of severe  adverse  reaction  associated  with a vaccine  and/or  severe  allergic 
reaction (eg, anaphylaxis) to any  component of the investigational product or any 
diphtheria toxoid –containing or CRM 197-containing vaccine.  
3. History  of microbiologically  proven invasive disease caused by  group B streptococcus.  
4. Immunocompromised  participants  with known  or suspected  immunodeficiency.  
5. Bleeding  diathesis  or condition  associated  with prolonged  bleeding  that would  in the 
opinion of the investigator contraindicate intramuscular injection.  
6. Other medical or psychiatric condition including recent (within the past year) or active 
suicidal ideation/behavior or laboratory abnormality that may increase the risk of study 
participation  or, in the investigator’s  judgment,  make  the participant  inappropriate  for the 
study.  
Prior/Concomitant Therapy:  
7. Previous vaccination with any licensed or investigational GBS vaccine, or planned 
receipt  during  the participant’s  participation  in the study  (through  the 6-month  follow -up 
visit [Visit 3]).  
8. Vaccination  within  5 years  with tetanus  and diphtheria  toxoids  and acellular  pertussis – 
containing vaccines (Tdap) before investigational product administration.  
9. Participants  who receive  treatment  with immunosuppressive  therapy,  including  cytotoxic 
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned 
receipt through the 1 -month follow -up visit (Visit 2).  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  27  
 10. Vaccination with diphtheria - or CRM 197-containing vaccine(s) from 6 months before 
investigational  product  administration,  or planned  receipt  through  the 1-month  follow -up 
visit.  
11. Receipt  or planned  receipt  of blood/plasma  products  or immunoglobulin,  from  60 days 
before investigational product administration through the 1 -month follow -up visit.  
Prior/Concurrent Clinical Study Experience:  
12. Participation  in other  studies  involving  investigational  drug(s)  within  28 days prior  to 
study entry and/or during study participation.  Participation in purely observational 
studies is acceptable.  
Diagnostic Assessments:  
Not applicable.  
Other Exclusions:  
13. Investigator site staff or Pfizer employees directly involved in the conduct of the study, 
site staff otherwise  supervised  by the investigator,  and their respective  family  members.  
5.3. Lifestyle Considerations  
5.3.1.  Contraception  
The investigator  or his or her designee,  in consultation  with the participant,  will confirm  that 
the participant has selected an appropriate method of contraception for the individual 
participant and her partner(s) from the permitted list of contraception methods  
(see Appendix 4, Section 10.4.3 ) and will confirm that the participant has been instructed in 
its consistent and correct use.  At time points indicated in the SoA, the investigator or 
designee will inform the participant of the need to use highly effective contraception 
consistently  and correctly  and document the conversation and the participant’s affirmation in 
the participant’s  chart  (participants  need  to affirm  their consistent  and correct  use of at least 1 
of the selected methods of contraception) considering that their risk for pregnancy may have 
changed since the last visit.  In addition, the investigator or designee will instruct the 
participant to call immediately if the selected contraception method is discontinued or if 
pregnancy is known or suspected in the participant or partner.  
5.4. Screen  Failures  
Screen failures  are defined as  participants  who consent to participate in the clinical  study  but 
are not subsequently randomly assigned to study intervention.  A minimal set of screen 
failure  information  is required  to ensure  transparent  reporting  of screen  failure  participants  to 
meet the CONSORT publishing requirements and to respond to queries from regulatory 
authorities.  Minimal information includes demography, screen failure details, eligibility 
criteria, and any SAE.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  28  
 Individuals  who do not meet  the criteria  for participation  in this study  (screen  failure)  may be 
rescreened under a different participant number if they later meet eligibility criteria.  
5.5. Criteria  for Temporarily  Delaying  Enrollment/Randomization/Administration  of 
Study Intervention  
5.5.1.  Temporary  Delay  Criteria  
The following  conditions  are temporary  or self-limiting  and a participant  may be vaccinated 
and/or have blood drawn in the study once the condition(s) has/have resolved and no other 
exclusion  criteria  are met. The prevaccination  immunogenicity  blood  draw  and vaccination 
should take place on the same day (Visit 1).  
5.5.1.1.  Criteria  for Temporarily  Delaying  Vaccine  Administration  
• Current  febrile  illness  (body  temperature  ≥100.4°F  [≥38.0°C])  or other  acute  illness 
within 48 hours before investigational product administration.  
• Receipt  of any inactivated  vaccine  or otherwise  nonlive  vaccine  within  14 days and any 
live vaccine within 28 days before investigational product administration.  
• Receipt of short -term (<14 days) systemic corticosteroids.  Investigational product 
administration  should  be delayed  until systemic  corticosteroid  use has been  discontinued 
for at least 30 days.  Inhaled/nebulized, intra -articular, intrabursal, or topical (skin or 
eyes) corticosteroids are permitted.  
5.5.1.2.  Criteria  for Temporarily  Delaying  Blood  Draw  
• Receipt  of antibiotic  therapy  within  72 hours  before  blood  draw.  Note:  Topical 
antibiotics are permitted.  
6. STUDY INTERVENTION(S)  AND CONCOMITANT THERAPY  
Study  intervention  is defined  as any investigational  intervention(s),  marketed  product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study 
participant according to the study protocol.  
For the purposes  of this protocol,  the term investigational  product  may be used 
synonymously with study intervention.  
6.1. Study  Intervention(s)  Administered  
For this study,  the investigational  products  are GBS6  (20 µg CPS/serotype/dose,  which  is 
equivalent to a 120 -µg/0.5 -mL dose), Tdap, and placebo (normal saline).  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  29  
 6.1.1.  GBS6  
GBS6 is composed of serotypes Ia, Ib, II, III, IV, and V CPSs individually  conjugated to the 
CRM 197 carrier protein.  CCI  
. There is  1 dose  level (20  µg CPS/serotype/dose  per vaccine  dose of 
120 µg). 
CCI  designed  to 
deliver the intended dose in a 0.5 -mL injection volume.  
6.1.2.  Tdap  
US-licensed  Tdap  will be provided  by the sponsor  to each study  site. 
Investigational sites will be provided with details of which US -licensed Tdap will be 
provided prior to the start of enrollment.  The active ingredients of Tdap will contain the 
following (per 0.5 -mL dose): 5 Lf (limits of flocculation) of TTd, 2 Lf of DTd, acellular 
pertussis  antigens  (2.5 µg of inactivated  pertussis  toxin,  5 µg of FHA,  and 3 µg of PRN,  5 µg 
of FIM).  
The Tdap  will also contain  the following  excipient  concentrations:  1.5 mg AlPO 4, ≤5 µg of 
residual formaldehyde, <50 ng residual glutaraldehyde, and 3.3 mg phenoxyethanol.  
Note: The stopper of the Tdap vial may  contain natural rubber latex.  
6.1.3.  Placebo  
The placebo  for the GBS6  vaccine  and Tdap  will be a sterile  normal  saline  solution  for 
injection (0.9% NaCl injection, in a 0.5 -mL dose).  
Placebo will be provided by  the sponsor to each study  site. 
Placebo  will be packaged  within  cartons  labeled  by Pfizer  or its designee  in accordance  with 
current guidelines and applicable local and legal regulatory requirements.  
6.1.4.  Administration  
Participants  will receive  2 injections  at Visit  1 in accordance  with the study’s  SoA. 
A 120 -µg dose of GBS6 (0.5 mL) and Tdap, a 120 -µg dose of GBS6 (0.5 mL) and normal 
saline  placebo,  or normal  saline  placebo  and Tdap  will be administered  intramuscularly  by an 
unblinded site staff member or designee.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  30  
 Location  of Injection  at Visit  1 
 
Formulation  Site of Vaccination  
GBS6  (20 µg CPS/serotype/dose) 
Tdap  Left deltoid muscle 
Right  deltoid  muscle  
GBS6  (20 µg CPS/serotype/dose) 
Placebo  Left deltoid muscle 
Right  deltoid  muscle  
Placebo 
Tdap  Left deltoid muscle 
Right  deltoid  muscle  
 
Standard  vaccination  practices  must  be observed  and vaccine  must  not be injected  into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction  should  be available  in accordance  with local  guidelines  for standard 
immunization practices.  
Administration  of study  interventions  should  be performed  by an appropriately  qualified, 
GCP -trained, and vaccine -experienced member of the study staff (eg, physician, nurse, 
physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by 
local, state, and institutional guidance.  
Study  intervention  administration details  will be recorded  on the CRF.  
6.2. Preparation/Handling/Storage/Accountability  
1. The investigator  or designee  must  confirm  appropriate  temperature  conditions  have  been 
maintained during transit for all study interventions received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Investigational  product  will be shipped  at +2°C  to +8°C  to each study  site after required 
regulatory and legal documents have been received by the sponsor.  Upon receipt  
at the study  site, the investigational  product  should  be immediately  transferred  to 
a +2°C to +8°C temperature -monitored refrigerator for storage.  
3. Only participants enrolled in the study may receive study intervention and only 
authorized  site staff may supply  or administer  study  intervention.  All study  interventions 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated recording) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.  At a minimum, daily minimum and 
maximum temperatures for all site storage locations must be documented and available 
upon request.  Data for nonworking days must indicate the minimum and maximum 
temperatures since previously documented for all site storage locations upon return to 
business.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  31  
 4. Any excursions  from  the study  intervention  label  storage  conditions  should  be reported  to 
Pfizer upon discovery along with any actions taken.  The site should actively pursue 
options for returning the study intervention to the storage conditions described in the 
labeling,  as soon  as possible.  Once  an excursion  is identified,  the study  intervention  must 
be quarantined and not used until Pfizer provides permission to use the study  
intervention.  Specific  details  regarding  the definition  of an excursion  and information  the 
site should report for each excursion will be provided to the site in the IP manual.  
5. Any storage  conditions  stated  in the SRSD  will be superseded  by the storage  conditions 
stated on the label.  
6. Study  interventions  should  be stored  in their original  containers.  
7. See the IP  manual  for storage  conditions  of the study  intervention.  
8. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible  for study  intervention  accountability,  reconciliation,  and record  maintenance 
(ie, receipt, reconciliation, and final disposition records), such as the IPAL or  
sponsor -approved  equivalent.  All study  interventions  will be accounted  for using  a study 
intervention accountability form/record.  
9. Further guidance and information for the final disposition of unused study interventions 
are provided in the IP manual.  All destruction must be adequately documented.  If 
destruction  is authorized  to take place  at the investigator  site, the investigator  must  ensure 
that the materials are destroyed in compliance with applicable environmental regulations, 
institutional policy, and any special instructions provided by Pfizer.  
Upon  identification  of a product  complaint,  notify  the sponsor  within  1 business  day of 
discovery as described in the IP manual.  
6.2.1.  Preparation  and Dispensing  
See the IP manual for instructions on how to prepare the investigational products for 
administration.  Investigational products should be prepared and dispensed by an 
appropriately qualified and experienced unblinded member of the study staff (eg, physician, 
nurse,  physician’s  assistant,  nurse  practitioner,  pharmacy  assistant/technician,  or pharmacist) 
as allowed by local, state, and institutional guidance.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  32  
 6.3. Measures  to Minimize  Bias:  Randomization  and Blinding  
6.3.1.  Allocation  to Study  Intervention  
Allocation (randomization) of participants to investigational product groups will proceed 
through the use of an IRT system (IWR).  The unblinded site personnel will be required to 
enter or select information including but not limited to the user’s ID and password, the 
protocol number, and the participant number.  The unblinded site personnel will then be 
provided with an investigational product assignment, randomization number, and DU or 
container number when study intervention is being supplied via the IRT system.  The IRT 
system  will provide  a confirmation  report  containing  the participant  number,  randomization 
number, and DU or container number assigned.  The confirmation report must be stored by 
the unblinded site personnel in the unblinded site files.  
Study  intervention will be dispensed at Visit 1 only  as summarized in the SoA. 
The study -specific  IRT reference  manual  and IP manual  will provide  the contact  information 
and further details on the use of the IRT system.  
6.3.2.  Blinding of the Site Personnel  
This is an observer -blinded  study,  as the appearance  of GBS6,  Tdap,  and placebo  will not be 
matched.  The study staff dispensing, preparing, and administering the vaccine will be 
unblinded, but all other study personnel, including the principal investigator and the 
participant, will be blinded.  The principal investigator will assign the responsibility of 
unblinded dispenser and unblinded administrator to persons who will not participate in the 
evaluation of any study participant.  More than 1 unblinded dispenser/administrator may be 
assigned.  A member of the study site staff or clinic pharmacy should fulfill this role.  
Contact  between  the unblinded  dispenser/administrator  and study  participants  should  be kept 
to a minimum.  The investigator, study coordinator, and any site staff other than the 
unblinded dispenser/administrator must not be allowed to know the investigational product 
assigned to any study participant and must not be allowed to see the investigational product 
containers.  
6.3.3.  Blinding of the Sponsor  
Sponsor study team members will remain blinded to vaccine assigned/received at the 
participant level.  In an event that unblinded results need to be submitted for regulatory 
communications  prior  to study  team  unblinding,  efforts  will be made  to ensure  study  team 
members involved in participant assessments are blinded.  
Laboratory  personnel  performing  the immunologic  assays  will remain  blinded  to vaccine 
assigned/received throughout the study.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  33  
 6.3.4.  Breaking the Blind  
The IRT will be programmed with blind -breaking instructions.  In case of an emergency, the 
investigator has the sole responsibility for determining if unblinding of a participant’s 
investigational product assignment is warranted.  Participant safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact the sponsor prior to 
unblinding a participant’s investigational product assignment unless this could delay further 
management of the participant.  If a participant’s investigational product assignment is 
unblinded, the sponsor must be notified within 24 hours after breaking the blind.  The date 
and reason that the blind was  broken must  be recorded in the source documentation and CRF.  
The study -specific  IRT reference  manual  and IP manual  will provide  the contact  information 
and further details on the use of the IRT system.  
6.4. Study  Intervention  Compliance  
All doses  of investigational  product  will be administered  by the appropriately  qualified  and 
designated study staff at the investigator site.  
6.5. Concomitant  Therapy  
6.5.1.  Prohibited  Nonstudy  Vaccines  and Medications  During  the Study  
• Nonstudy  investigational  vaccines,  drugs,  or medical  devices  are prohibited  during  the 
course of the study.  
• Nonstudy diphtheria - and CRM 197-containing vaccines, blood/plasma products or 
immunoglobulins,  and immunosuppressive  therapy  are prohibited  during  the course  of 
the study.  
• Other  nonstudy  vaccines  may not be given  concomitantly  with the investigational  product 
or within 14 days after investigational product administration (except during an outbreak 
or pandemic situation).  
6.5.2.  Permitted  Nonstudy  Vaccines  and Medications  During  the Study  
• Licensed  influenza  vaccine  may be given  during  the study  14 days after investigational 
product administration.  
• If medically necessary  (eg, pandemic), licensed vaccines  may be given  at any  time.  
• Inhaled/nebulized,  intra-articular,  intrabursal,  or topical  (skin  or eyes)  corticosteroids  are 
permitted.  
• The use of antipyretics and other pain medication to treat symptoms associated with 
investigational  product  administration  is permitted  during  participant  participation  in the 
study.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  34  
 • The use of prophylactic  antipyretic  medication,  while  permitted,  is not recommended  on 
the day of the investigational product administration.  
• Any other  vaccines  that are medically  required  by local  recommendations  and permitted 
by the protocol  may be administered  concomitantly  with GBS6  and/or  Tdap  but must  be 
given in a different limb.  
• Hormonal  contraceptives  that meet  the requirements  of this study  are allowed  to be used 
in participants who are WOCBP (see Appendix 4 ). 
6.5.3.  Recording  Nonstudy  Vaccinations  and Concomitant  Medications  
The name and date of administration for all nonstudy  vaccinations received from the time of 
signing  of the ICD to Visit  3 will be collected  and recorded  in the CRF.  Antibiotic  treatment 
taken from the signing of the ICD to Visit 3 will be recorded.  
Details of any medications that the participant is currently taking for medical conditions at 
enrollment  (time  of signing  of the ICD  at Visit  1) will be recorded  in the CRF.  Additionally, 
only medications taken to treat AEs from the signing of the ICD through Visit 2 and MAEs 
and SAEs from the signing of the ICD through Visit 3 will be recorded in the CRF  
(per Section  8.3.1 ). 
6.6. Dose Modification  
Not applicable.  
6.7. Intervention After the End of the Study  
No intervention  will be provided  to study  participants  at the end of the study.  
7. DISCONTINUATION  OF STUDY  INTERVENTION  AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
Since  this is a single -dose study,  this section  is not applicable.  
7.2. Participant Discontinuation/Withdrawal From the Study  
A participant  may withdraw  from  the study  at any time at his/her  own request.  Reasons  for 
discontinuation from the study include the following:  
• Withdrawn  consent  (refused  further  follow -up); 
• Lost to follow -up; 
• Medication  error  without  associated  AE; 
• Death;  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  35  
 • Study  terminated by  sponsor;  
• AEs;  
• Protocol violation;  
• Pregnancy;  
• No longer meets eligibility  criteria.  
After investigational product administration at Visit 1, participants who request to 
discontinue  further  study  procedures  (eg, blood  draw)  at an  upcoming  visit will be asked  to 
remain  in the study  for protocol -specified  safety  follow -up procedures.  The only exception 
to this is  when a participant  specifically  withdraws consent  for any  further  contact with her. 
If a participant withdraws from the study, she may request destruction of any remaining 
samples  taken  and not tested,  and the investigator  must  document  any such requests  in the 
site study records and notify the sponsor accordingly.  
If the participant  withdraws  from  the study  and also withdraws  consent  (see Section  7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.  
When  a participant  withdraws  from  the study  because  of an SAE,  the SAE  must  be recorded 
on the CRF and reported on the Vaccine SAE Reporting Form.  
Lack  of completion  of all or any of the withdrawal/early  termination  procedures  will not be 
viewed as protocol deviations so long as the participant’s safety was preserved.  
Participants  who have  received  the investigational  product  will not be replaced  regardless  of 
the reason for withdrawal.  
7.2.1.  Withdrawal of Consent  
Participants  who request  to discontinue  receipt  of study  intervention  will remain  in the study 
and must continue to be followed for protocol -specified follow -up procedures.  The only 
exception  to this is when  a participant  specifically  withdraws  consent  for any further  contact 
with her or persons previously authorized by the participant to provide this information.  
Participants should notify the investigator in writing of the decision to withdraw consent  
from  future  follow -up, whenever  possible.  The withdrawal  of consent  should  be explained  in 
detail in the medical records by the investigator as to whether the withdrawal is only from 
further receipt of the study intervention or also from the study procedures and/or 
posttreatment study follow -up, and entered on the appropriate CRF page.  In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in 
accordance with local law.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  36  
 7.3. Lost  to Follow -up 
A participant  will be considered  lost to follow -up if she repeatedly  fails to return  for 
scheduled visits and is unable to be contacted by the study site.  
The following  actions  must  be taken  if a participant  fails to return  to the clinic  for a required 
study visit or cannot be reached for scheduled telephone call:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned  visit schedule  and ascertain  whether  or not the participant  wishes  to and/or 
should continue in the study;  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make  every  effort  to regain  contact  with the participant  (where  possible,  3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address  or local  equivalent  methods).  These  contact  attempts  should  be documented 
in the participant’s medical record;  
• Should  the participant  continue  to be unreachable,  she will be considered  to have 
withdrawn from the study.  
8. STUDY ASSESSMENTS AND  PROCEDURES  
The investigator  (or an appropriate  delegate  at the investigator  site) must  obtain  a signed  and 
dated ICD before performing any study -specific procedures.  
The date of birth  will be collected  to critically  evaluate  the immune  response  and safety 
profile by age.  
Study  procedures  and their timing  are summarized  in the SoA. Protocol  waivers  or 
exemptions are not allowed.  
Safety issues should be discussed with the sponsor immediately upon occurrence or 
awareness  to determine  whether  the participant  should  continue  or discontinue  study 
intervention.  
Adherence  to the study  design  requirements,  including  those  specified  in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  37  
 Every effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances  outside  the control  of the investigator  that may make  it unfeasible  to perform 
the test.  In these cases, the investigator must take all steps necessary to ensure the safety 
and well -being of the participant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and any corrective and preventive 
actions that he/she has taken to ensure that required processes are adhered to as soon as 
possible.  The study team must be informed of these incidents in a timely manner.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment  instructions  and contact  information  will be provided  to the investigator  site prior 
to initiation of the study.  
8.1. Efficacy  and/or  Immunogenicity  Assessments  
Blood samples (approximately 50 mL/visit) for immunogenicity assessments will be 
collected  from  all participants  prior  to vaccination  (Day  1) and at 1 month  after vaccination 
(Visit 2)  
Sample  collection,  processing,  storage,  and shipping  information  can be found  in the ISF or 
equivalent  manual.  Sera will be used for immunogenicity  assessments,  assay  development, 
and routine assay maintenance.  
8.1.1.  GBS  Vaccine  Antibody Testing  
Concentrations of anticapsular IgG for the 6 serotypes (Ia, Ib, II, III, IV, and V) will be 
determined  from  the GBS6+Tdap  and GBS6+placebo  groups  for each blood  sample  at Day 1 
and at 1 month after vaccination and reported as IgG concentrations.  
Participants  from  these  2 groups  will be identified  by an independent  unblinded  statistician; 
additional participants from the placebo+Tdap group may be included in order to maintain 
the blinding of randomization assignment.  
8.1.2.  Tdap Antibody Testing  
Sera will be collected from the coadministration and placebo+Tdap groups and they will be 
assayed for IgG antibodies to Tdap antigens in a multiplexed Luminex bead -based assay 
(DTP -6 IgG).  IgG levels  to diphtheria,  tetanus,  and pertussis  antigens  (pertussis  toxin,  PRN, 
FHA, and FIM) will be measured and reported in either IU/mL (diphtheria and tetanus) or 
EU/mL (pertussis toxin, FHA, FIM and PRN).  
Participants  from  these  2 groups  will be identified  by an independent  unblinded  statistician; 
additional  participants  from  the GBS6+placebo group  may be included  in order  to maintain 
the blinding of randomization assignment.  
Immunogenicity  assays  will be performed  at Pfizer  Vaccine  Research  & Development 
Laboratory  located  at 401 North  Middletown  Road,  Pearl  River,  NY 10965  and/or  at a 
facility designated by Pfizer.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  38  
 8.1.3.  Biological Samples  
Serum samples will be used only  for scientific research.  Each sample will be labeled with a 
code so that the laboratory personnel testing the samples will not know the participant’s 
identity.  Samples  that remain  after performing  assays  outlined  in the protocol  may be stored 
by Pfizer.  Unless a time limitation is required by local regulations or ethical requirements, 
the samples will be stored for up to 15 years after the end of the study and then destroyed.  
If allowed  by the ICD,  stored  samples  may be used for additional  testing  to better  understand 
the immune responses to the vaccine(s) under study in this protocol, to inform the 
development of other products, and/or for vaccine -related assay work supporting vaccine 
programs.  No testing of the participant’s genetic material will be performed.  
The participant  may request  that her samples,  if still identifiable,  be destroyed  at any time; 
however,  any data already  collected  from  those  samples  will still be used for this research. 
The biological samples may be shared with other researchers as long as confidentiality is 
maintained and no testing of the participant’s genetic material is performed.  
8.2. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA. Unscheduled  clinical 
laboratory measurements may be obtained at any time during the study to assess any 
perceived safety issues.  
8.2.1.  Participant  E-Diary  
Participants will be required to use an e -diary, based on appropriate technology, and 
will be asked  to monitor  and record  local  reactions,  systemic  events,  temperature,  and 
antipyretic/pain  medication  used to treat symptoms  each evening  for 7 days following  
vaccination.  Participants may be able to utilize their own devices to access this technology, 
or use a device provided by the sponsor.  This system, hereafter referred to as the 
participant’s  e-diary,  allows  recording  of these  assessments  only within  a fixed  time window, 
thus providing the accurate representation of the participant’s experience at that time.  Data 
on local  reactions,  systemic  events,  temperature,  and antipyretic/pain  medication  used to treat 
symptoms reported on the e -diary will be transferred electronically to the e -diary vendor, 
where they will be available for review by investigators, their qualified designees, and 
sponsor staff at all times via an internet -based portal.  At intervals agreed to by the vendor 
and Pfizer, these data will be transferred electronically to Pfizer for analysis and reporting.  
These data do not need to be reported by the investigator in the CRF.  However, if a 
participant  withdraws  because  of prompted  events  reported  in the e-diary,  the event(s)  should 
be recorded on the AE page of the CRF, regardless of whether the investigator considers the 
event(s) to be clinically significant.  
Investigators  (or appropriately  qualified  designee)  are required  to review  the e-diary  data 
online to evaluate participant compliance and as part of the ongoing safety review.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  39  
 The investigator  or designee  must  contact  the participant  in order  to obtain  stop dates  for any 
reactions ongoing on the last day that the e -diary was completed.  The stop dates should be 
documented in the source documents and the information entered in the CRF.  
8.2.2.  Grading  Scale  for Prompted  Events  
The grading  scales  used in this study  to assess  AEs as described  below  are based  on concepts 
outlined in the FDA CBER guidelines on toxicity  grading scales for healthy  adult volunteers 
enrolled in preventive vaccine clinical trials.36 
8.2.2.1.  Local  Reactions  
From Day 1 to Day 7, where Day 1 is the day of vaccination, participants will be asked to 
assess redness, swelling, and pain at the injection site of the left arm and to record the 
symptoms in the e -diary  in the evening.  Redness and swelling of the injection site of the left 
arm will be measured and recorded in measuring device units (range: 1 to 21 and >21), and 
then categorized during analysis as mild, moderate, or severe based on the grading scale in 
Table 1 . Measuring device units can be converted to centimeters according to the following 
scale:  1 measuring  device  unit = 0.5 cm. Pain at the vaccine  injection  site of the left arm will 
be assessed by the participant as mild, moderate, or severe according to the grading scale in 
Table 1 . A participant with a severe (Grade 3 or above) local reaction of the left arm will be 
prompted to contact the investigator to perform an unscheduled visit and assess the reaction.  
Only  an investigator  is able to classify  a participant’s  local  reaction  as Grade  4, after physical 
examination of the participant or documentation from another medically qualified source  
(eg, emergency room or hospital record), or, in the case of pain at the injection site only, 
telephone contact with the participant.  If a participant experiences a Grade 4 local reaction, 
the investigator must immediately notify the sponsor.  Site staff will educate the participant 
regarding  signs  and symptoms  that would  prompt  site contact.  The procedure  for notification 
of the sponsor is provided in the study documentation.  
If a local reaction persists beyond the end of the e -diary period following vaccination, the 
participant  will be requested  to report  that information  and/or  any new AEs that develop  to 
the investigator.  The investigator will enter this additional information in the CRF.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  40  
 Table  1. Local Reaction Grading Scale  
 
 Mild 
(Grade  1) Moderate 
(Grade  2) Severe 
(Grade  3)a  
Grade  4b 
Pain  at injection 
site Does  not interfere 
with activity  Repeated use of 
nonnarcotic pain 
reliever  >24 hours 
or interferes with  
activity  Any use of narcotic 
pain reliever or 
prevents daily 
activityc Emergency room 
visit or 
hospitalization  for 
severe pain at the  
injection  site 
Erythema/ 
redness  >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)  >5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)  >10.0  cm 
(>20  measuring 
device units)  Necrosis  or 
exfoliative 
dermatitis  
Induration/ 
swelling  >2.0 cm to 5.0 cm 
(5 to 10 measuring 
device units)  >5.0 cm to 10.0 cm 
(11 to 20 measuring 
device units)  >10.0  cm 
(>20  measuring 
device units)  Necrosis  
a. Participants  experiencing  ≥ Grade  3 local  reactions  are to be seen by the study  site. Refer  to the 
Unscheduled Visits section ( Section 8.11.4 ) for further guidance.  
b. Grade  4 assessment  should  be made  by the investigator.  Grade  4 will not be collected  in the electronic 
diary but will be recorded as an AE on the case report form.  
c. Prevents  daily  activity,  ie, results  in missed  days of work  or school  or is otherwise  incapacitating,  or 
includes use of narcotics for analgesia.  
 
8.2.2.2.  Systemic  Events  
From  Day 1 to Day 7, where  Day 1 is the day of vaccination,  participants  will be asked  to 
assess nausea/vomiting, diarrhea, headache, fatigue, muscle pain, and joint pain and to 
record the symptoms in the e -diary in the evening.  The symptoms will be assessed by  
the participant as mild, moderate, or severe according to the grading scale in Table 2 . 
Participants will also be instructed to contact site staff if they experience any possible 
Grade 4 prompted systemic event (ie, emergency room visit or hospitalization for 
nausea/vomiting,  diarrhea,  headache,  fatigue,  muscle  pain,  or joint pain)  within  7 days after 
vaccination.  Study  staff may also contact  the participant  to obtain  additional  information  on 
Grade 3 events entered into the e -diary.  
Only an investigator is able to classify a participant’s systemic event as Grade 4, after 
physical examination of the participant or documentation from another medically qualified 
source (eg, emergency  room or hospital record) or telephone contact with the participant.  If 
a participant  experiences  a Grade  4 systemic  event,  the investigator  must  immediately  notify 
the sponsor.  The procedure for notification of the sponsor is provided in the study 
documentation.  
Further, if a systemic event persists beyond the end of the e -diary period following 
vaccination, the participant will be requested to report that information and/or any  new AEs 
that develop  to the investigator.  The investigator  will enter  this additional  information  in the 
CRF.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  41  
 Table  2. Systemic Event Grading Scale  
 
 Mild 
(Grade  1) Moderate 
(Grade  2) Severe 
(Grade  3)a Grade  4b 
Nausea/vomiting  No interference  with 
activity  or 1-2 times 
in 24 hours  Some  interference 
with activity  or >2 
times in 24 hours  Prevents daily 
activity;  requires  IV 
hydration  Emergency room 
visit or 
hospitalization  for 
hypotensive shock  
Diarrhea  2-3 loose  stools  in 24 
hours  4-5 loose  stools  in 24 
hours  ≥6 loose  stools  in 
24 hours  Emergency room 
visit or 
hospitalization  for 
severe diarrhea  
Headache  No interference  with 
activity  Repeated use of 
nonnarcotic pain 
reliever >24 hours or  
some  interference  with 
activity  Significant;  any use 
of narcotic pain 
reliever  or prevents 
daily activityc Emergency room 
visit or 
hospitalization  for 
severe headache  
Fatigue  
(= tiredness  in 
diaries)  No interference  with 
activity  Some  interference 
with activity  Significant;  prevents 
daily activityc Emergency room 
visit or  
hospitalization  for 
severe fatigue  
Muscle pain No interference  with 
activity  Some  interference 
with activity  Significant;  prevents 
daily activityc Emergency room 
visit or  
hospitalization for 
severe muscle pain 
Joint  pain No interference  with 
activity  Some  interference 
with activity  Significant;  prevents 
daily activityc Emergency room 
visit or 
hospitalization  for 
severe joint pain  
a. Participants  experiencing  ≥ Grade  3 systemic  events  are to be seen by the study  site. Refer  to the 
Unscheduled Visits section ( Section 8.11.4 ) for further guidance.  
b. Grade  4 assessment  should  be made  by the investigator.  Grade  4 will not be collected  in the electronic 
diary but will be collected as an AE on the case report form.  
c. Prevents  daily  routine  activity,  ie, results  in missed  days of work  or school  or is otherwise  incapacitating, 
or includes use of narcotics for analgesia.  
 
8.2.2.3.  Fever  
In order  to record  information  on fever,  a digital  thermometer  will be given  to the participant 
with instructions on how to measure oral temperature at home.  Temperature will be 
collected in the evening daily for 7 days following vaccination (Days 1 to 7, where Day  1 is 
the day of vaccination) and at any time during the 7 days that fever is suspected.  Fever is 
defined  as an oral temperature  of ≥100.4°F  (≥38.0°C).  The highest  temperature  for each day 
will be recorded in the e -diary.  In the event of a fever on Day 7, temperature will be 
collected daily until fever has resolved (1 day of temperature less than 100.4°F [38.0°C] in 
order to collect a stop date in the CRF).  A participant with a fever ≥102.1°F (≥39.0°C) will 
be prompted to contact the investigator to assess the fever and perform an unscheduled visit 
as appropriate.  Study  staff must also contact the participant to obtain additional information 
if a temperature of ≥102.1°F is entered into an e -diary.  Temperature will be measured and 
recorded to 1 decimal place and then grouped into ranges for the analysis according to  
Table  3. 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  42  
 Table 3. Ranges  for Fever  
 
100.4°F  to 101.1°F  (38.0°C  to 38.4°C)  
101.2°F  to 102.0°F  (>38.4°C  to 38.9°C)  
102.1°F  to 104.0°F  (>38.9°C  to 40.0°C)  
>104.0°F  (>40.0°C)  
 
8.2.3.  Use of Antipyretic/Pain  Medication  
From  Day 1 to Day 7, where  Day 1 is the day of vaccination,  the participant  will be asked  to 
record the use of antipyretic and/or pain medication used to treat symptoms reported in the  
e-diary  in the evening.  
8.2.4.  Clinical  Safety  Laboratory  Assessments  
Clinical safety  laboratory assessments will  not be collected in this study.  
8.2.5.  Pregnancy  Testing  
Pregnancy tests will be urine tests, but must have a sensitivity of at least 25 mIU/mL. 
Pregnancy tests will be performed in WOCBP at the times listed in the SoA, immediately 
before the administration of each vaccine dose.  A negative pregnancy test result will be 
required prior to the participant’s receiving the study intervention.  Pregnancy tests may also 
be repeated if requested by IRBs/ECs or if required by local regulations.  In the case of a 
positive  confirmed  pregnancy,  the participant  will be withdrawn  from  administration  of study 
intervention but may remain in the study.  
8.3. Adverse  Events  and Serious  Adverse  Events  
The definitions  of an AE and an SAE  can be found  in Appendix  3. 
AEs may arise from symptoms or other complaints reported by the participant (or, when 
appropriate,  by a caregiver,  surrogate,  or the participant’s  legally  authorized  representative), 
or they may arise from clinical findings of the investigator or other healthcare providers 
(clinical signs, test results, etc).  
The investigator  and any qualified  designees  are responsible  for detecting,  documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1 ). 
Each  participant  will be questioned  about  the occurrence  of AEs in a nonleading  manner.  
In addition,  the investigator  may be requested  by Pfizer  Safety  to obtain  specific  follow -up 
information in an expedited fashion.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  43  
 8.3.1.  Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”)  for each participant  begins  from  the time the participant  provides  informed  consent, 
which is obtained before the participant’s participation in the study (ie, before undergoing 
any study -related procedure and/or receiving study intervention), through and including 
Visit 2 (1 month after vaccination) for AEs, and through and including Visit 3 (6 months 
after vaccination) for MAEs and SAEs.  
Follow -up by the investigator  continues  throughout  and after the active  collection  period  and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.  
For participants  who are screen  failures,  the active  collection  period  ends when  screen  failure 
status is determined.  
If the participant  withdraws  from  the study  and also withdraws  consent  for the collection  of 
future information, the active collection period ends when consent is withdrawn.  
If a participant  permanently  discontinues  or temporarily  discontinues  study  intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the Vaccine SAE Reporting Form.  
Investigators are not obligated to actively seek AEs or SAEs after the participant has 
concluded study participation.  However, if the investigator learns of any SAE, including a 
death,  at any time after a participant  has completed  the study,  and he/she  considers  the event 
to be reasonably related to the study intervention, the investigator must promptly  report the 
SAE to Pfizer using the Vaccine SAE Reporting Form.  
8.3.1.1.  Reporting  SAEs  to Pfizer Safety  
All SAEs occurring in a participant during the active collection period as described in 
Section  8.3.1  are reported  to Pfizer  Safety  on the Vaccine  SAE  Reporting  Form  immediately 
upon awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within  
24 hours  of it being available.  
8.3.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF  
All nonserious  AEs and SAEs  occurring  in a participant  during  the active  collection,  which 
begins after obtaining informed consent, as described in Section 8.3.1, will be recorded on 
the AE section of the CRF.  
The investigator  is to record  on the CRF  all directly  observed  and all spontaneously  reported 
AEs and SAEs reported by the participant.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  44  
 8.3.2.  Method  of Detecting  AEs and SAEs  
The method  of recording,  evaluating,  and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care  will be taken  not to introduce  bias when  detecting  AEs and/or  SAEs.  Open -ended  and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts.  For each event, the investigator must pursue and 
obtain  adequate  information  until resolution,  stabilization,  the event  is otherwise  explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ). 
In general,  follow -up information  will include  a description  of the event  in sufficient  detail  to 
allow for a complete medical assessment of the case and independent determination of 
possible causality.  Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety.  
Further  information  on follow -up procedures  is given  in Appendix  3. 
8.3.4.  Regulatory  Reporting  Requirements  for SAEs  
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations  and ethical  responsibilities  towards  the safety  of participants  and the safety  of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify both the local regulatory authority and other 
regulatory  agencies  about  the safety  of a study  intervention  under  clinical  investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.  
Investigator  safety  reports  must  be prepared  for SUSARs  according  to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives SUSARs or other specific safety information (eg, summary or 
listing  of SAEs)  from  the sponsor  will review  and then file it along  with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate according to local requirements.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  45  
 8.3.5.  Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives  unplanned  direct  contact  with or exposure  to the study  intervention.  Such  exposure 
may or may  not lead to the occurrence of an AE or SAE.  Persons at risk for environmental 
exposure include healthcare providers, family members, and others who may be exposed.  
An environmental  exposure  may include  exposure  during  pregnancy,  exposure  during 
breastfeeding, and occupational exposure.  
Any such exposure  to the study  intervention  under  study  are reportable  to Pfizer  Safety 
within 24 hours of investigator awareness.  
8.3.5.1.  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female  participant  is found  to be pregnant  while  receiving  or after discontinuing 
study intervention.  
• A female nonparticipant is found to be pregnant while being exposed or having been 
exposed  to study  intervention  due to environmental  exposure.  Below  are examples  of 
environmental EDP:  
• A female  family  member  or healthcare  provider  reports  that she is pregnant  after 
having been exposed to the study intervention by ingestion, inhalation, or skin 
contact.  
• A male  family  member  or healthcare  provider  who has been  exposed  to the study 
intervention by ingestion, inhalation, or skin contact then exposes his female 
partner prior to or around the time of conception.  
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness,  irrespective  of whether  an SAE  has occurred.  The initial  information  submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
• If EDP  occurs  in a participant,  the investigator  must  report  this information  to Pfizer 
Safety on the Vaccine SAE Reporting Form and an EDP Supplemental Form, 
regardless of whether an SAE has occurred.  Details of the pregnancy will be 
collected after the start of study intervention and until 6 months after vaccination.  
• If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety using the Vaccine SAE Reporting Form and EDP 
Supplemental Form.  Since the exposure information does not pertain to the 
participant  enrolled  in the study,  the information  is not recorded  on a CRF;  however, 
a copy of the completed Vaccine SAE Reporting Form is maintained in the ISF.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  46  
 Follow -up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP  reports  with an unknown  outcome.  The investigator  will follow  the pregnancy  until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
follow -up to the initial EDP Supplemental Form.  In the case of a live birth, the structural 
integrity of the neonate can be assessed at the time of birth.  In the event of a termination, 
the reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Abnormal  pregnancy  outcomes  are considered  SAEs.  If the outcome  of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs.  Additional information about pregnancy outcomes that are reported to 
Pfizer Safety as SAEs follows:  
• Spontaneous  abortion,  including  miscarriage  and missed  abortion;  
• Neonatal deaths that occur within 6 months of birth should be reported, without 
regard  to causality,  as SAEs.  In addition,  infant  deaths  after 6 months  should  be 
reported as SAEs when the investigator assesses the infant death as related or 
possibly related to exposure to the study intervention.  
Additional information regarding the EDP may be requested by the sponsor.  Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays).  In the case of paternal exposure, the 
investigator  will provide  the participant  with the Pregnant  Partner  Release  of Information  
Form  to deliver  to his partner.  The investigator  must  document  in the source  documents  that 
the participant  was given  the Pregnant  Partner  Release  of Information  Form  to provide  to his 
partner.  
8.3.5.2.  Exposure During Breastfeeding  
An exposure  during  breastfeeding  occurs  if: 
• A female  participant  is found  to be breastfeeding  while  receiving  or after 
discontinuing study intervention.  
• A female nonparticipant is found to be breastfeeding while being exposed or having 
been exposed to study intervention (ie, environmental exposure).  An example of 
environmental exposure during breastfeeding is a female family member or  
healthcare  provider  who reports  that she is breastfeeding  after having  been  exposed  to 
the study intervention by inhalation or skin contact.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  47  
 The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred.  The 
information must be reported using the Vaccine SAE Reporting Form.  When exposure 
during breastfeeding occurs in the setting of environmental exposure, the exposure 
information  does not pertain  to the participant  enrolled  in the study , so the information  is not 
recorded on a CRF.  However, a copy of the completed Vaccine SAE Reporting Form is 
maintained in the ISF.  
An exposure during breastfeeding report is not created when a Pfizer drug specifically 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized  use. However,  if the infant  experiences  an SAE  associated  with such a drug,  the 
SAE is reported together with the exposure during breastfeeding.  
8.3.5.3.  Occupational Exposure  
An occupational  exposure  occurs  when  a person  receives  unplanned  direct  contact  with the 
study intervention, which may or may not lead to the occurrence of an AE.  Such persons 
may include healthcare providers, family  members, and other roles that are involved in the 
trial participant’s care.  
The investigator must report occupational exposure to Pfizer Safety within 24 hours of the 
investigator’s  awareness,  regardless  of whether  there  is an associated  SAE.  The information 
must be reported using the Vaccine SAE Reporting Form.  Since the information does not 
pertain  to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed Vaccine SAE Reporting Form is maintained in the ISF.  
8.3.6.  Cardiovascular  and Death  Events  
Not applicable.  
8.3.7.  Disease -Related  Events  and/or  Disease -Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.3.8.  Adverse  Events  of Special  Interest  
Not applicable.  
8.3.8.1.  Lack  of Efficacy  
Lack  of efficacy  in an approved indication should be reported as an SAE to Pfizer Safety.  
8.3.9.  Medical Device Deficiencies  
Not applicable.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  48  
 8.3.10.  Medication  Errors  
Medication errors may result from the administration or consumption of the study 
intervention  by the wrong  participant,  or at the wrong  time,  or at the wrong  dosage  strength.  
Exposures  to the study  intervention  under  study  may occur  in clinical  trial settings,  such as 
medication errors.  
 
Safety Event  Recorded  on the CRF  Reported on the Vaccine SAE 
Reporting  Form  to Pfizer  Safety 
Within 24 Hours of Awareness  
Medication  errors  All (regardless  of whether 
associated with an AE)  Only  if associated with an SAE 
 
Medication  errors  include:  
• Medication  errors  involving participant  exposure  to the  study  intervention;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study participant.  
Such  medication  errors  occurring  to a study  participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
In the event of a medication dosing error, the sponsor should be notified within 24 hours.  
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator,  the medication  error  is recorded  on the medication  error  page  of the CRF  and, if 
applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of the 
CRF.  
Medication  errors  should  be reported  to Pfizer  Safety  within  24 hours  on a Vaccine  SAE 
Reporting Form only when associated with an SAE.  
Other  examples  include, but  are not  limited to: 
• The administration of expired study  intervention;  
• The administration of an incorrect study  intervention;  
• The administration  of an incorrect  dosage;  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  49  
 • The administration  of study  intervention  that has undergone  temperature  excursion  from 
the specified storage range, unless it is determined by the sponsor that the study 
intervention under question is acceptable for use.  
8.4. Treatment  of Overdose  
For this study, any  dose of investigational  product  greater  than 1 dose within  a 24-hour time 
period will be considered an overdose.  
The sponsor  does not recommend  specific  treatment  for an overdose. 
In the event of an overdose, the investigator should:  
1. Contact the medical monitor within 24 hours.  
2. Closely  monitor the  participant  for any AEs/SAEs.  
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in 
the CRF.  
4. Overdose  is reportable to Safety  only when associated with an SAE.  
8.5. Pharmacokinetics  
Pharmacokinetic parameters are not evaluated in this study.  
8.6. Pharmacodynamics  
Pharmacodynamic  parameters  are not  evaluated in  this study.  
8.7. Genetics  
Genetics  (specified  analyses)  are not evaluated  in this study.  
8.8. Biomarkers  
Biomarkers are not evaluated in this study.  
8.9. Immunogenicity  Assessments  
Please  refer  to Section  8.1. 
8.10. Health  Economics  
Health  economics/medical  resource  utilization  and health  economics  parameters  are not 
evaluated in this study.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  50  
 8.11. Study Procedures  
If, because of a medical situation (such as disease outbreak or pandemic), study  visits cannot 
be conducted  in person  at the study  site, visit procedures  should  be conducted  remotely  or via 
telephone, as is feasible.  
It is anticipated  that the procedures  below  will be conducted  in a stepwise  manner;  ensure 
that procedures listed prior to administration of the vaccine are conducted prior to 
vaccination.  
8.11.1.  Visit 1 – Vaccination (Day 1) 
• Obtain  written  informed  consent  before  performing  any study -specific  procedures.  
• Assign a participant number using the IRT system.  
• Obtain  and record  the participant  demography  (including  date of birth,  sex, race,  and 
ethnicity).  The full date of birth will be collected to critically evaluate the immune 
response and safety profile by age.  
• Obtain  and record  any medical  history  of clinical  significance.  
• Perform physical examination evaluating any clinically significant abnormalities within 
the following  body  systems:  general  appearance;  skin;  head,  eyes,  ears, nose,  and throat; 
heart; lungs; abdomen; musculoskeletal; extremities; neurological; and lymph nodes. 
Abnormal results must be recorded on source documents and the Physical Examination 
page of the CRF.  
• Prior  to vaccination,  perform  a urine  pregnancy  test for WOCBP  and ensure  the result  is 
negative.  
• Record  nonstudy  vaccinations  and medications  as described  in Section  6.5.3 . 
• Ensure  and document  that all of the inclusion  criteria,  none  of the exclusion  criteria,  and 
none of the temporary delay criteria are met.  
• Prior  to vaccination,  measure  vital signs,  including  weight,  height,  sitting  blood  pressure 
and pulse rate, respiratory rate, and temperature (oral).  
• Verify  the participant’s  understanding  of and compliance  with the protocol  requirements 
for contraception.  Instruct  the participant  to use appropriate  contraceptives  until 28 days 
after administration of investigational product and document the conversation and the 
participant’s affirmation in the participant’s source document.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  51  
 • A blinded site staff member will use the IRT system to obtain the participant’s 
randomization number.  An unblinded site staff member will use the IRT to assign the 
investigational product container number, and will prepare the investigational product 
and deliver  it to the investigational  product  administrator.  Please  refer  to the IP manual 
for further instruction on this process.  
• Prior  to vaccination,  collect  a blood  sample  of approximately  50 mL for immunogenicity 
assessments.  
• The unblinded administrator administers a 0.5 -mL injection of investigational product 
into the deltoid muscle of the left arm and a 0.5 -mL injection of investigational product 
into the deltoid  muscle  of the right  arm (see Section  6.1.4 ). Please  refer  to the IP manual 
for further instruction on this process.  
• Blinded  site staff must  observe  the participant  for at least 30 minutes  after investigational 
product administration for any acute reactions.  Record any immediate AEs in the 
participant’s source documents, on the AE page of the CRF, and on an SAE form as 
applicable.  
• Issue/activate  e-diary  device.  Ask the participant  to complete  the e-diary  from  Day 1 to 
Day 7, with Day 1 being the day of vaccination.  
• Issue the participant a measuring device to measure local reactions and a digital 
thermometer  to measure  daily  temperatures,  and provide  instructions  on their use. 
• Ask the participant to contact the site staff or investigator immediately if she is prompted 
by the e -diary  from Day  1 to Day  7 following vaccination to determine if an unscheduled 
visit is required (eg, redness or swelling at the injection site measuring >20 measuring 
device  units  [>10.0  cm]).  Remind  participants  that study  staff may contact  them  to obtain 
additional information on Grade 3 (or above) events entered into the e -diary.  
• Ask the participant  to contact  the site staff or investigator  if an MAE  (eg, emergency 
room) or hospitalization occurs.  
• Provide  the participant  with a contact  card (see Section  10.1.10  for a description  of the 
contact card).  
• Record AEs as described in Section 8.3. 
• Complete  the participant’s  source  documents.  
• The investigator  or an authorized  designee  completes  the CRF  and an unblinded  site staff 
member updates the investigational product accountability records.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  52  
 • The investigator  or appropriately  qualified  designee  reviews  the e-diary  data online 
following  vaccination  to evaluate  participant  compliance  and as part of the ongoing 
safety review.  
8.11.2.  Visit  2 – 1-Month  Follow -up Visit  (28-38 Days  After  Visit  1) 
• Ensure that the participant continues to be eligible for the study, meets none of the 
participant  withdrawal  criteria  as described  in Section  7, and meets  none  of the blood 
draw temporary delay criteria as described in Section 5.5.1.2 . 
• Verify  the participant’s  understanding  of and compliance  with the protocol  requirements 
for contraception.  
• Collect a blood  sample of  approximately  50 mL  for immunogenicity assessments.  
• Review  the participant’s  e-diary  data and collect  the e-diary.  Collect  stop dates  of any 
e-diary events ongoing on the last day that the e -diary was completed and record stop 
dates in the CRF.  
• Record  nonstudy  vaccinations  and concomitant  medications  as described  in Section  6.5.3 . 
• Record AEs as described in Section 8.3. 
• Complete  the participant’s  source  documents.  
• The investigator  or an authorized  designee  completes  the CRF.  
8.11.3.  Visit  3 – 6-Month  Telephone  Call Follow -up Visit  (160-200 Days  After  Visit  1) 
• Ensure  that the participant  continues  to be eligible  for the study  and meets  none  of the 
participant withdrawal criteria as described in Section 7 . 
• Record  nonstudy  vaccinations  and concomitant  medications  as described  in Section  6.5.3 . 
• Record  MAEs  and SAEs  as described  in Section  8.3. 
• Complete  the participant’s  source  documents.  
• The investigator  or an authorized  designee  completes  the CRF.  
8.11.4.  Unscheduled Visits  
If the participant reports redness or swelling at the injection site measuring >20 measuring 
device units (>10.0 cm), fever ≥102.1°F (≥39.0°C), or severe injection site pain, severe 
nausea/vomiting, severe diarrhea, severe headache, severe fatigue, severe muscle pain, or 
severe  joint pain,  a telephone  contact  must  occur  as soon  as possible  between  the participant 
and the investigator or a medically qualified member of the study site staff to assess if an  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  53  
 unscheduled  visit is required.  A site visit must  be scheduled  as soon  as possible  to assess  the 
extent of the reaction unless:  
• The participant is  unable to attend the unscheduled visit, or 
• The reaction is  no longer present at the time of the telephone contact, or 
• The participant  recorded  an incorrect  value  in the e-diary  (confirmation  of an e-diary  data 
entry error), or  
• The investigator  determined  it was not needed.  
This telephone  contact  will be recorded  in the CRF  and in the participant’s  source 
documentation.  
If the participant  is unable  to attend  the unscheduled  visit,  any ongoing  reactions  must  be 
assessed at the next scheduled visit (Visit 2 and/or Visit 3).  
The reactions should be assessed by the investigator or a medically qualified member of the 
study  staff,  such as a study  physician  or a study  nurse,  as applicable  to the investigator’s  local 
practice, who will:  
• Measure oral temperature.  
• Measure  minimum  and maximum  diameters  of redness  (if present).  
• Measure  minimum  and maximum  diameters  of swelling  (if present).  
• Assess  any injection  site pain that is present  in accordance  with the grading  scale 
provided in Section 8.2.2 . 
• Assess  any systemic  events  (nausea/vomiting,  diarrhea,  headache,  fatigue,  muscle  pain, 
or joint pain) that are present in accordance with the grading scale provided in  
Section 8.2.2 . 
The investigator  or an authorized  designee  will complete  the unscheduled  visit page  of the 
CRF.  
Participants will also be instructed to contact site staff if they experience any possible  
Grade 4 prompted systemic event (ie, emergency room visit or hospitalization for 
nausea/vomiting, diarrhea, headache, fatigue, muscle pain, or joint pain) within 7 days  after 
vaccination.  Study staff may contact the participant to obtain additional information on 
Grade  3 events  entered  into the e-diary.  Lastly,  participants  will be instructed  to contact  the 
site to report any significant illness, medical event, or hospitalization that occurs during the 
study  period.  The site should  determine  if an unscheduled  visit to further  evaluate  the event 
is warranted in all such cases.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  54  
 9. STATISTICAL  CONSIDERATIONS  
Methodology for summary and statistical analyses of the data collected in this study is 
described here and further detailed in a SAP, which will be maintained  by the sponsor.  The 
SAP may modify what is outlined in the protocol where appropriate; however, any major 
modifications  of the primary  endpoint  definitions  or their analyses  will also be reflected  in a 
protocol amendment.  
9.1. Estimands and Statistical Hypotheses  
9.1.1.  Statistical Hypotheses  
There  are no statistical  hypotheses  defined  in the study.  
9.1.2.  Estimands 
Primary  (Safety):  
In participants  receiving  at least 1 dose of the investigational  product:  
• The proportion  of participants  reporting  prompted  local  reactions  within  7 days following 
investigational product administration.  
• The proportion  of participants  reporting  prompted  systemic  events  within  7 days 
following investigational product administration.  
• The proportion  of participants  reporting  AEs through  1 month  following  investigational 
product administration.  
• The proportion  of participants  reporting  MAEs  and SAEs  through  6 months  following 
investigational product administration.  
Missing  e-diary  data will not be imputed;  missing  AE dates  and missing  AE severity  will be 
handled according to Pfizer safety rules.  
Primary  (Immunogenicity):  
In participants  receiving  all doses  of the investigational  products  and in compliance  with the 
key protocol criteria (evaluable participants):  
• The difference in proportions of participants with anti –tetanus toxoid antibody 
concentrations  ≥0.1 IU/mL  measured  1 month  after vaccination  between  the GBS6+Tdap 
group and the placebo+Tdap group.  
• The difference in proportions of participants with anti –diphtheria toxoid antibody 
concentrations  ≥0.1 IU/mL  measured  1 month  after vaccination  between  the GBS6+Tdap 
group and the placebo+Tdap group.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  55  
 • GMR,  estimated  by the GMR  of anti–pertussis  toxin  antibodies  from  the GBS6+Tdap 
group to the placebo+Tdap group measured 1 month after vaccination.  
• GMR,  estimated  by the GMR  of anti–filamentous  hemagglutinin  
(anti-FHA)  antibodies  from  the GBS6+Tdap  group  to the placebo+Tdap  group  measured 
1 month after vaccination.  
• GMR, estimated by the GMR of antipertactin (anti -PRN) antibodies from the 
GBS6+Tdap  group  to the placebo+Tdap  group  measured  1 month  after vaccination.  
• GBS  capsular  polysaccharide  (CPS)  serotype -specific  IgG GMR,  estimated  by the GMR 
of GBS CPS serotype -specific IgG antibodies from the GBS6+Tdap group to the 
GBS6+placebo group measured 1 month after vaccination.  
These estimands estimate the vaccine effect in the hypothetical setting where participants 
follow the study schedules and protocol requirements as directed.  Missing serology results 
will not be imputed,  as missing  completely  at random  (MCAR)  is assumed.  For participants 
who discontinue  from  the study  or have  major  protocol  violations,  all postdiscontinuation  or 
violation observations will be censored.  
Secondary  
Not applicable. 
Exploratory  
In participants  receiving  all doses  of the investigational  products  and in compliance  with the 
key protocol criteria (evaluable participants):  
• Proportions  of participants  with anti–tetanus  toxoid  and anti–diphtheria  toxoid  antibody 
concentrations ≥0.1 IU/mL  measured before vaccination and 1 month after vaccination 
for both the GBS6+Tdap group and the placebo+Tdap group.  
• Proportions  of participants  with anti–tetanus  toxoid  and anti–diphtheria  toxoid  antibody 
concentrations ≥1.0 IU/mL  measured before vaccination and 1 month after vaccination 
for both the GBS6+Tdap group and the placebo+Tdap group.  
• The differences  in proportions  of participants  with anti–tetanus  toxoid  and 
anti–diphtheria  toxoid  antibody  concentrations  ≥0.1 IU/mL  measured  1 month  after 
vaccination between the GBS6+Tdap group and the placebo+Tdap group.  
• Geometric mean concentrations (GMCs) of anti –tetanus toxoid, anti –diphtheria toxoid, 
and anti–pertussis  component  (pertussis  toxin,  FHA,  PRN,  and FIM)  antibodies  measured 
before vaccination and 1 month after vaccination for both the GBS6+Tdap group and the 
placebo+Tdap group.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  56  
 • Geometric mean fold rises (GMFRs) of anti –tetanus toxoid, anti –diphtheria toxoid, and 
anti–pertussis component (pertussis toxin, FHA, PRN, and FIM) antibodies measured 
from  before  vaccination  to 1 month  after vaccination  for both the GBS6+Tdap  group  and 
the placebo+Tdap group.  
• GBS capsular polysaccharide (CPS) serotype -specific IgG GMCs measured before and  
1 month  after vaccination  for both the GBS6+Tdap  group  and the GBS6+placebo  group.  
• GBS  capsular  polysaccharide  (CPS)  serotype -specific  IgG GMFRs  measured  from  before 
vaccination to 1 month after vaccination for both GBS6+Tdap group and GBS6+placebo 
group.  
9.2. Sample Size Determination  
The study  sample  sizes  are not based  on any formal  statistical  hypothesis  test considerations. 
The study  aims  to have  a sufficient  number  of participants  in order  to describe  the safety  and 
immunogenicity  of concomitantly administered Tdap and GBS6.  With approximately  
100 participants  to be enrolled  in each group,  the lower  bound  of the 2-sided  95% CI for the 
IgG GMR, estimated by the GMR of GBS CPS serotype -specific IgG antibodies from the 
GBS6+Tdap group to the GBS6+placebo group measured 1 month after vaccination, is 
approximately 0.40, 0.38, 0.53, 0.48, 0.63, and 0.46, assuming that there was no inherent 
difference between these 2 groups, and the maximum SD (natural logarithm scale) is 3.09, 
3.27, 2.15, 2.48, 1.58, and 2.65 for serotypes Ia, Ib, II, III, IV, and V, respectively, from 
Study C1091001, with a 10% nonevaluable rate.  
With  a similar  assumption  of no inherent  difference  between  groups,  a similar  nonevaluable 
rate, and 100 enrolled  participants  in each group,  the lower  bound  of the 2-sided  95% CI for 
the GMR,  estimated  by the GMR  of anti–pertussis  toxin  antibodies,  anti-FHA  antibodies,  or 
anti-PRN antibodies from the GBS6+Tdap group to the placebo+Tdap group measured  
1 month after vaccination, is approximately 0.74, 0.78, and 0.72, assuming maximum SDs 
(natural logarithm scale) of 1.01, 0.85, and 1.12 for anti –pertussis toxin antibody, anti -FHA 
antibody, anti -PRN antibody endpoints, respectively, and the lower bound of the 2 -sided  
95% CI for the difference in proportions of participants with anti –tetanus toxoid antibody 
concentrations ≥0.1 IU/mL and participants with anti –diphtheria toxoid antibody 
concentrations ≥0.1 IU/mL measured 1 month after vaccination between the GBS6+Tdap 
group  and the placebo+Tdap  group  is approximately  -0.05 and -0.076,  respectively,  assuming 
that the proportions are 0.99 and 0.94 for anti –tetanus toxoid antibody and anti –diphtheria 
toxoid antibody endpoints from Study B1971015.  
The primary  safety  objective  includes  the endpoints  for local  reactions,  systemic  events,  AEs, 
MAEs, and SAEs.  
Table  4 shows  the probability  of detecting  at least 1 event  (local  reactions,  systemic  events, 
AEs, MAEs, or SAEs).  The number of participants in each study group is 100, which 
provides a 86% chance of observing at least 1 event in a group, assuming a true rate of at 
least 2%.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  57  
 Table 4. Probability  of Observing at  Least 1  Event by  Assumed  True  Event Rates  
 
Assumed  True  Event  Percentage  Probability  
0.10%  9.52%  
0.50%  39.4%  
1.0%  63.4%  
2.0%  86.7%  
3.0%  95.2%  
4.0%  98.3%  
5.0%  99.4%  
 
9.3. Analysis Sets 
For purposes  of analysis,  the following  analysis sets  are defined:  
 
Population  Description  
Enrolled  All participants who sign the ICD.  
Randomly assigned to 
investigational  product  All participants  who are assigned  a randomization  number  in 
the IWR system.  
Evaluable  All participants who are eligible, receive all doses of the 
investigational products to which they were randomized, 
have blood drawn for assay testing within the specified time 
frame  for 1 month  after vaccination,  have  at least 1 valid  and 
determinate  assay  result  at the 1-month  postvaccination  visit, 
and have no major protocol violations.  
Modified  intent -to-treat 
(mITT)  All randomized  participants  who receive  at least 1 dose of the 
investigational products and have at least 1 valid and 
determinate assay result after vaccination.  
Safety  All participants who receive at least 1 dose of the 
investigational  products  and have  at least 1 valid  postdose 
assessment.  
 
9.4. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe  the analyses  and procedures  for accounting  for missing,  unused,  and spurious  data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
9.4.1.  Safety Analyses  
All safety  analyses  will be  performed on  the safety  population.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  58  
  
Endpoint  Statistical Analysis Methods  
Primary  • Point estimates and exact 2 -sided 95% CIs will be calculated using the 
Clopper -Pearson  method  for the proportion  of participants  reporting  each 
event (local reactions, systemic events, AEs, MAEs, and SAEs) for each 
vaccine group.  
• AEs and SAEs  will be categorized  according  to MedDRA  terms.  A 
3-tiered approach will be used to summarize AEs.  For both Tier 1 and 
Tier 2 events, the 95% CIs for the difference in the proportion of 
participants reporting events between the GBS6+Tdap group and the 
GBS6+placebo group, and between the GBS6+Tdap group and the 
placebo+Tdap group, will be calculated using the test statistic proposed 
by Miettinen and Nurminen.  In addition, for Tier 1 events (if any), the 
asymptotic p -values will also be presented for the difference in the 
proportion  of participants  reporting  events  based  on the same  test statistic 
and unde r the assumption  that the test statistic  is asymptotically  normally 
distributed.  There are no preidentified Tier 1 events for this study.  A 
MedDRA preferred term is defined as a Tier 2 event if there are 1% of 
participants in at least 1 vaccine group reporting the event.  Descriptive 
summary statistics (counts and proportions) will be provided for Tier 3 
events for each vaccine group.  
The safety  analyses  are based  on the safety  population.  Participants  will 
be summarized according to the vaccine group corresponding to the 
investigational  product  they actually  received.  Missing  e-diary  data will 
not be imputed; missing AE dates and missing AE severity will be 
addressed using the Pfizer safety rules.  
Secondary  • N/A 
Exploratory  • N/A 
 
9.4.2.  Immunogenicity  Analyses  
 
Endpoint  Statistical Analysis Methods  
Primary  • The differences (GBS6+Tdap group minus placebo+Tdap group) in 
proportions of participants with anti –tetanus toxoid and anti –diphtheria 
toxoid  antibody  concentrations  ≥0.1 IU/mL  at 1 month  after vaccination 
will be calculated, and associated 2 -sided 95% CIs will be calculated 
using the Miettinen and Nurminen method  
• GMRs of the GBS6+Tdap group to the placebo+Tdap group for the 
anti–pertussis  toxin,  anti-FHA,  and anti-PRN  antibody  concentrations  at 
1 month after vaccination will be calculated, along with associated  
2-sided 95% CIs.  The GMR will be calculated as the group mean 
difference of logarithmically transformed antibody levels and 
transformed back to the original units.  Two (2) -sided 95% CIs will also 
be obtained  by calculating  CIs using  Student’s  t distribution  for the mean  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  59  
  
Endpoint  Statistical Analysis Methods  
 difference  of measures  on the logarithmically  transformed  assay  results 
and transforming confidence limits back to the original units.  
• GBS6 serotype -specific IgG GMR of the GBS6+placebo group to the 
GBS6+Tdap  group  at 1 month  after vaccination  will be calculated,  along 
with associated 2 -sided 95% CIs, using the same method as for  
anti–pertussis  toxin,  anti-FHA,  and anti-PRN  antibody  GMRs.  
CCI  
  
  
This analysis  is based  on the evaluable  population.  An additional  analysis 
will be performed based on the mITT population if there is enough 
difference between the mITT population and the evaluable population.  
Participants  will be summarized  according  to the vaccine  group  to which 
they were randomized.  Missing serology data will not be imputed.  
Exploratory  • Point  estimates  and the exact  2-sided  95% CIs will be calculated  using 
the Clopper -Pearson method for the proportion of participants with 
anti–tetanus  toxoid  and anti–diphtheria  toxoid  antibody  concentrations  
≥0.1 IU/mL  at each available  time point  for the GBS6+Tdap  and 
placebo+Tdap groups.  
• Point  estimates  and the exact  2-sided  95% CIs will be calculated  using 
the Clopper -Pearson method for the proportion of participants with 
anti–tetanus  toxoid  and anti–diphtheria  toxoid  antibody  concentrations  
≥1.0 IU/mL  at each available  time point  for the GBS6+Tdap  and 
placebo+Tdap groups.  
• The differences (GBS6+Tdap group minus placebo+Tdap group) in 
proportions  of participants  with anti–tetanus  toxoid  and anti–diphtheria 
toxoid  antibody  concentrations  ≥1.0 IU/mL  measured  at each available 
time point after vaccination will be calculated and associated 2 -sided 
95% CIs will be calculated using the Miettinen and Nurminen method.  
• Geometric mean concentrations (GMCs) of anti -TTd, anti -DTd, 
anti–pertussis  toxin,  anti-FHA,  anti-PRN,  and anti-FIM antibodies  at 
each available time point will be descriptively summarized for the  
GBS6+Tdap and placebo+Tdap groups, along with associated 2 -sided 
95% CIs. The GMC  will be calculated  as the mean  of the antibody  titers 
after the logarithm transformation and then transformed back to its 
original  scale.  Two (2)-sided  95% CIs will be constructed  by calculating 
a CI for the mean of the logarithmically transformed assay results 
computed based on Student’s t distribution and transforming confidence 
limits back to the original units.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  60  
  
Endpoint  Statistical Analysis Methods  
 • Geometric mean fold rises (GMFRs) from before vaccination to each 
available time point after vaccination will be provided for anti -TTd, 
anti-DTd, anti –pertussis toxin, anti -FHA, anti -PRN, and anti -FIM 
antibodies for both the GBS6+Tdap and placebo+Tdap groups, along 
with associated 2 -sided 95% CIs.  The GMFR will be calculated as the 
mean of the difference of logarithmically transformed antibody titers 
(postvaccination minus prevaccination for each participant) and 
transformed back to the original units.  Two (2) -sided 95% CIs will be 
computed  by calculating  CIs for the mean  difference  of measures  on the 
logarithmically transformed assay results using Student’s t distribution 
and transforming back to the original units.  
• GBS  capsular  polysaccharide  (CPS)  serotype -specific  IgG GMCs  at each 
available time point will be descriptively summarized for the 
GBS6+Tdap and GBS6+placebo groups, along with associated 2 -sided 
95% CIs, using the same method as for anti -TTd, anti -DTd, anti – 
pertussis toxin, anti -FHA, anti -PRN, and anti -FIM antibody GMCs.  
• GBS  capsular  polysaccharide  (CPS)  serotype -specific  IgG GMFRs  from 
before vaccination to each available time point after vaccination will be 
provided, for both the GBS6+Tdap and GBS6+placebo groups, along 
with associated  2-sided  95% CIs using  the same  method  as for anti-TTd, 
anti-DTd, anti –pertussis toxin, anti -FHA, anti -PRN, and anti -FIM 
antibody GMFRs.  
• GBS  capsular  polysaccharide  (CPS)  serotype -specific  empirical  RCDCs 
for IgG antibody concentrations at each available postvaccination time 
point will be presented, for both the GBS6+Tdap and GBS6+placebo 
groups.  
• Point estimates and the exact 2 -sided 95% CIs will be calculated using 
the Clopper -Pearson method for the proportions of participants with 
serotype -specific  GBS -positive  vaginal/rectal  cultures  at each available 
time point for all 3 groups.  
IgG antibody  concentrations  denoted  as BLQ  will be imputed  as 0.5 × LLOQ 
for GMC and GMT analyses, respectively.  
The above analyses are based on the evaluable population.  An additional 
analysis  will be performed  based  on the mITT  population  if there  is enough 
difference between the mITT population and the evaluable population.  
Participants  will be summarized  according  to the vaccine  group  to which 
they were randomized.  Missing serology data will not be imputed.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  61  
 9.5. Interim  Analyses  
There  will be 1 planned  interim  analysis  when  Visit  2 (1-month  postvaccination  visit)  safety 
and immunogenicity data from all participants are available.  
9.6. Data Monitoring Committee or Other Independent Oversight Committee  
This study will use an established E -DMC.  The E -DMC is independent of the study team 
and includes  only external  members.  The E-DMC  charter  describes  the role of the E-DMC 
in more detail.  
The E -DMC will be responsible for ongoing monitoring of the safety of participants in the 
study according to the charter.  The recommendations made by the E -DMC to alter the 
conduct  of the study  will be forwarded  to the appropriate  Pfizer  personnel  for final decision. 
Pfizer will forward such decisions, which may include summaries of aggregate analyses of 
safety data, to regulatory authorities, as appropriate.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  62  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  
10.1. Appendix  1: Regulatory, Ethical,  and Study Oversight Considerations  
10.1.1.  Regulatory  and Ethical  Considerations  
This study  will be conducted in accordance with the protocol and with the following:  
• Consensus  ethical  principles  derived  from  international  guidelines  including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable  ICH GCP  guidelines;  
• Applicable  laws and  regulations, including  applicable privacy  laws.  
The protocol,  protocol amendments,  ICD,  SRSD(s), and  other  relevant documents  
(eg, advertisements) must be reviewed and approved by the sponsor and submitted to an 
IRB/EC  by the investigator  and reviewed  and approved  by the IRB/EC  before  the study  is 
initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes  made  to the study  design,  except  for changes  necessary  to eliminate  an immediate 
hazard to study participants.  
The investigator  will be responsible  for the following:  
• Providing  written  summaries  of the status  of the study  to the IRB/EC  annually  or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;  
• Notifying  the IRB/EC  of SAEs  or other  significant  safety  findings  as required  by 
IRB/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements  of 21 CFR,  ICH guidelines,  the IRB/EC,  European  regulation  536/2014 
for clinical studies (if applicable), and all other applicable local regulations.  
10.1.1.1.  Reporting  of Safety  Issues  and Serious  Breaches  of the Protocol  or ICH  GCP  
In the event  of any prohibition  or restriction  imposed  (ie, clinical  hold)  by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately.  
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken  by the investigator  to protect  the study  participants  against  any immediate  hazard,  and 
of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware 
of. 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  63  
 10.1.2.  Financial Disclosure  
Investigators  and subinvestigators  will provide  the sponsor  with sufficient,  accurate  financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities.  Investigators 
are responsible  for providing  information  on financial  interests  during  the course  of the study 
and for 1 year after completion of the study.  
10.1.3.  Informed  Consent  Process  
The investigator  or his/her  representative  will explain  the nature  of the study,  including  the 
risks and benefits, to the participant and answer all questions regarding the study.  The 
participant should be given sufficient time and opportunity to ask questions and to decide 
whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary.  Participants will be 
required  to sign a statement  of informed  consent  that meets  the requirements  of 21 CFR  50, 
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC 
or study center.  
The investigator  must  ensure  that each study  participant  is fully  informed  about  the nature 
and objectives of the study, the sharing of data related to the study, and possible risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data.  
The participant must be informed that her personal study -related data will be used by the 
sponsor  in accordance  with local  data protection  law. The level  of disclosure  must  also be 
explained to the participant.  
The participant  must  be informed  that her medical  records  may be examined  by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.  
The investigator  further  must  ensure  that each study  participant  is fully  informed  about  her 
right to access and correct her personal data and to withdraw consent for the processing of 
her personal data.  
The medical record must include a statement that written informed consent was obtained 
before  the participant  was enrolled  in the study  and the date the written  consent  was obtained. 
The authorized person obtaining the informed consent must also sign the ICD.  
Participants  must  be reconsented  to the most  current  version  of the ICD(s)  during  their 
participation in the study.  
A copy of the ICD(s) must be provided to the participant. 
Participants  who are rescreened  are required  to sign a new ICD.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  64  
 10.1.4.  Data  Protection  
All parties  will comply  with all applicable  laws,  including  laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data.  
Participants’  personal  data will be stored  at the study  site in encrypted  electronic  and/or  paper 
form and will be password -protected or secured in a locked room to ensure that only 
authorized study staff have access.  The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study site will be responsible  
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by law.  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code.  Any 
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names  will not be transferred.  All other identifiable data transferred to the 
sponsor will be identified by this single, participant -specific code.  The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s  numerical  code  to her actual  identity  and medical  record  identification.  In case 
of data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study agreement and applicable privacy laws.  
10.1.5.  Dissemination of Clinical Study Data  
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com,  and other public registries in accordance with applicable local 
laws/regulations.  In addition,  Pfizer  reports  study  results  outside  of the requirements  of local 
laws/regulations pursuant to its SOPs.  
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete  manner  and are reported  regardless  of the outcome  of the study  or the country  in 
which the study was conducted.  
www.clinicaltrials.gov  
Pfizer  posts  clinical  trial results  on www.clinicaltrials.gov  for Pfizer -sponsored  interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product,  
regardless of the geographical location in which the study is conducted.  These results are 
submitted for posting in accordance with the format and timelines set forth by US law.  
EudraCT  
Pfizer  posts  clinical  trial results  on EudraCT  for Pfizer -sponsored  interventional  studies  in 
accordance with the format and timelines set forth by EU requirements.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  65  
 www.pfizer.com  
Pfizer  posts  public  disclosure  synopses  (CSR  synopses  in which  any data that could  be used 
to identify individual participants have been removed) on www.pfizer.com  for 
Pfizer -sponsored  interventional  studies  at the same  time the corresponding  study  results  are 
posted to www.clinicaltrials.gov.  
Documents  within  marketing  authorization  packages/submissions  
Pfizer  complies  with the European  Union  Policy  0070,  the proactive  publication  of clinical 
data to the EMA website.  Clinical data, under Phase 1 of this policy, includes clinical 
overviews,  clinical  summaries,  CSRs,  and appendices  containing  the protocol  and protocol 
amendments, sample CRFs, and statistical methods.  Clinical data, under Phase 2 of this 
policy, includes the publishing of individual participant data.  Policy 0070 applies to new 
marketing authorization applications submitted via the centralized procedure since  
01 January  2015  and applications  for line extensions  and for new indications  submitted  via 
the centralized procedure since 01 July 2015.  
Data Sharing  
Pfizer  provides  researchers  secure  access  to patient -level  data or full CSRs  for the purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class.  Pfizer will make available data from these trials  
24 months  after study  completion.  Patient -level  data will be anonymized  in accordance  with 
applicable  privacy  laws and regulations.  CSRs  will have  personally  identifiable  information 
redacted.  
Data  requests  are considered  from  qualified  researchers  with the appropriate  competencies  to 
perform  the proposed  analyses.  Research  teams  must  include  a biostatistician.  Data  will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.  
10.1.6.  Data Quality Assurance  
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted  to the sponsor  or designee  electronically  (eg, laboratory  data).  The investigator  is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
The investigator  must  ensure  that the CRFs  are securely  stored  at the study  site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by unauthorized third parties.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  66  
 The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents.  This 
verification may also occur after study completion.  It is important that the investigator(s) 
and their relevant  personnel  are available  during  the monitoring  visits  and possible  audits  or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy (eg, risk -based initiatives in operations and quality, 
such as risk management and mitigation strategies and analytical risk -based monitoring), 
methods,  responsibilities,  and requirements,  including  handling  of noncompliance  issues  and 
monitoring techniques (central, remote, or on -site monitoring), are provided in the 
monitoring plan.  
The sponsor  or designee  is responsible  for the data management  of this study,  including 
quality checking of the data.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized  site personnel are accurate,  complete,  and verifiable from source 
documents;  that the safety  and rights  of participants  are being  protected;  and that the study  is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period.  No records may be destroyed during 
the retention period without the written approval of the sponsor.  No records may be 
transferred to another location or party without written notification to the sponsor.  The 
investigator  must  ensure  that the records  continue  to be stored  securely  for as long as they are 
maintained.  
When  participant  data are to be deleted,  the investigator  will ensure  that all copies  of such 
data are promptly and irrevocably deleted from all systems.  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study.  Furthermore, the investigator will cooperate 
with the sponsor  or its agents  to prepare  the investigator  site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant's medical records.  The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent.  Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.  
10.1.7.  Source  Documents  
Source  documents  provide  evidence  for the existence  of the participant  and substantiate  the 
integrity of the data collected.  Source documents are filed at the investigator site.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  67  
 Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator  may need  to request  previous  medical  records  or transfer  records,  depending  on 
the study.  Also, current medical records must be available.  
The definition  of what  constitutes  source  data can be found  in ISF, which  is maintained  by 
the sponsor.  
Description  of the use of computerized  systems  is documented  in the data management  plan, 
which is maintained by the sponsor.  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized  site personnel are accurate,  complete,  and verifiable from source 
documents;  that the safety  and rights  of participants  are being  protected;  and that the study  is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.8.  Study and Site Start and Closure  
The study  start date is the date on which  the clinical  study  will be open  for recruitment  of 
participants.  
The first act of recruitment  is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor designee reserves the right to close the study  site or terminate the study  at any 
time for any reason at the sole discretion of the sponsor.  Study sites will be closed upon 
study  completion.  A study  site is considered  closed  when  all required  documents  and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time upon notification to the CRO if 
requested  to do so by the responsible  IRB/EC  or if such termination  is required  to protect  the 
health of study participants.  
Reasons  for the early  closure  of a study  site by the sponsor  may include  but are not limited 
to: 
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/EC  or local  health  authorities,  the sponsor's  procedures,  or GCP  guidelines;  
• Inadequate  recruitment of  participants by  the investigator;  
• Discontinuation of further study  intervention development.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  68  
 If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory  authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements.  The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study  termination  is also provided  for in the clinical  study  agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.9.  Publication  Policy  
The results of this study may be published or presented at scientific meetings by the 
investigator  after publication  of the overall  study  results  or 1 year after the end of the study 
(or study termination), whichever comes first.  
The investigator  agrees  to refer  to the primary  publication  in any subsequent  publications, 
such as secondary manuscripts, and submits all manuscripts or abstracts to the sponsor  
30 days before  submission.  This allows  the sponsor  to protect  proprietary  information  and to 
provide comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study - or Pfizer  
intervention -related  information  necessary  for the appropriate  scientific  presentation  or 
understanding of the study results.  
For all publications  relating  to the study,  the investigator  will comply  with recognized  ethical 
standards concerning publications and authorship, including those established by the 
International Committee of Medical Journal Editors.  
The sponsor will comply with the requirements for publication of the overall study results 
covering  all investigator  sites.  In accordance  with standard  editorial  and ethical  practice,  the 
sponsor will support publication of multicenter studies only in their entirety and not as 
individual site data.  In this case, a coordinating investigator will be designated by mutual 
agreement.  
Authorship of publications for the overall study results will be determined by mutual 
agreement  and in line with International  Committee  of Medical  Journal  Editors  authorship 
requirements.  
If publication  is addressed  in the clinical  study  agreement,  the publication  policy  set out in 
this section will not apply.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  69  
 10.1.10.  Sponsor’s  Qualified  Medical  Personnel  
The contact  information  for the sponsor's  appropriately  qualified  medical  personnel  for the 
study is documented in the study contact list located in the ISF.  
To facilitate access to appropriately qualified medical personnel on study -related medical 
questions  or problems,  participants  are provided  with an emergency  contact  card (ECC)  at 
the time of informed consent.  The ECC contains, at a minimum, (a) protocol and study 
intervention identifiers, (b) participant’s study identification number, (c) site emergency 
phone number active 24 hours/day, 7 days per week, and (d) Pfizer Call Center number.  
The contact number can also be used by investigator staff if they are seeking advice on 
medical questions or problems; however, it should be used only in the event that the 
established  communication  pathways  between  the investigator  site and the study  team  are not 
available.  
The ECC is intended to augment, but not replace, the established communication pathways 
between the investigator, site staff, and the study  team.  The ECC is to be used by  healthcare 
professionals not involved in the research study, only  as a means of reaching the investigator 
or site staff related  to the care of a participant.  The Pfizer  Call Center  number  should  only be 
used when the investigator and site staff cannot be reached.  The Pfizer Call Center number  
is not intended for use by the participant directly; if a participant calls that number directly, 
she will be directed back to the investigator site.  
10.2. Appendix  2: Clinical  Laboratory  Tests  
Not applicable.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  70  
 10.3. Appendix  3: Adverse  Events:  Definitions  and Procedures  for Recording, 
Evaluating, Follow -up, and Reporting  
10.3.1.  Definition of AE 
 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study 
participant,  temporally  associated  with the use of study  intervention,  whether  or not 
considered related to the study intervention.  
• Note:  An AE can therefore  be any unfavorable  and unintended  sign (including  an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of study intervention.  
 
 
Events  Meeting  the AE Definition  
• Any abnormal  laboratory  test results  (hematology,  clinical  chemistry,  or urinalysis) 
or other  safety  assessments  (eg, ECG,  radiological  scans,  vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator.  Any abnormal laboratory test 
results that meet any of the conditions below must be recorded as an AE:  
• Is associated  with accompanying  symptoms.  
• Requires  additional  diagnostic  testing  or medical/surgical  intervention.  
• Leads  to a change  in study  dosing  (outside  of any protocol -specified  dose 
adjustments) or discontinuation from the study, significant additional 
concomitant drug treatment, or other therapy.  
• Exacerbation  of a chronic  or intermittent  preexisting  condition,  including  either  an 
increase in frequency and/or intensity of the condition.  
• New  conditions  detected  or diagnosed  after study  intervention  administration,  even 
though it may have been present before the start of the study.  
• Signs,  symptoms,  or the  clinical sequelae  of a suspected  drug-drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention  or a concomitant  medication.  Overdose  per se will not be reported  as 
an AE/SAE unless it is an intentional overdose taken with possible  
suicidal/self -harming  intent.  Such  overdoses  should  be reported  regardless  of 
sequelae.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  71  
  
Events  NOT  Meeting  the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments  which  are associated  with the underlying  disease,  unless  judged  by the 
investigator to be more severe than expected for the participant’s condition.  
• The disease/disorder  being  studied  or expected  progression,  signs,  or symptoms  of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical  or surgical  procedure  (eg, endoscopy,  appendectomy):  the condition  that 
leads to the procedure is the AE.  
• Situations  in which  an untoward  medical  occurrence  did not occur  (social  and/or 
convenience admission to a hospital).  
• Anticipated  day-to-day fluctuations  of preexisting  disease(s)  or condition(s)  present 
or detected at the start of the study that do not worsen.  
 
10.3.2.  Definition of  an SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions  are met (eg, hospitalization  for signs/symptoms  of the disease  under  study,  death 
due to progression of disease).  
 
An SAE  is defined  as any untoward  medical  occurrence  that,  at any dose:  
a.  Results in  death  
b. Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
participant  was at risk of death  at the time of the event.  It does not refer  to an event  that 
hypothetically might have caused death if it were more severe.  
c.  Requires  inpatient  hospitalization  or prolongation  of existing  hospitalization  
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting.  Complications that occur during hospitalization are AEs.  If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious.  When  in doubt  as to whether  “hospitalization”  occurred  or was necessary,  the AE 
should be considered serious.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  72  
  
An SAE  is defined  as any untoward  medical  occurrence  that,  at any dose:  
Hospitalization  for elective  treatment  of a preexisting  condition  that did not worsen  from 
baseline is not considered an AE.  
d. Results  in persistent  disability/incapacity  
• The term disability  means  a substantial  disruption  of a person’s  ability  to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively  minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza,  and accidental  trauma  (eg, sprained  ankle)  which  may interfere  with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e.  Is a congenital  anomaly/birth  defect  
f. Is a suspected  transmission  via a Pfizer  product  of an infectious  agent,  pathogenic 
or nonpathogenic, is considered serious  
• The event may be suspected from clinical symptoms or laboratory findings 
indicating an infection in a participant exposed to a Pfizer product.  The terms 
“suspected  transmission”  and “transmission”  are considered  synonymous.  These 
cases are considered unexpected and handled as serious expedited cases by 
pharmacovigilance personnel.  Such cases are also considered for reporting as 
product defects, if appropriate.  
g. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting  is appropriate  in other  situations,  such as important  medical  events  that 
may not be immediately life -threatening or result in death or hospitalization but 
may jeopardize  the participant  or may require  medical  or surgical  intervention  to 
prevent one of the other outcomes listed in the above definition.  These events 
should usually be considered serious.  
• Examples  of such events  include  invasive  or malignant  cancers,  intensive  treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency or drug abuse.  
 
10.3.3.  Definition  of Medically  Attended  Adverse  Event  
An MAE  is defined  as a nonserious  AE that results  in an evaluation  at a medical  facility.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  73  
 10.3.4.  Definition  of Immediate  Adverse  Event  
Immediate  AEs,  defined  as AEs occurring  within  the first 30 minutes  after study  intervention 
administration.  
10.3.5.  Recording/Reporting  and Follow -up of AEs and/or  SAEs 
AE and SAE Recording/Reporting  
The table below summarizes the requirements for recording adverse events on the CRF 
and for reporting serious adverse events on the Vaccine SAE Reporting Form to Pfizer 
Safety.  These  requirements  are delineated  for 3 types  of events:  (1) SAEs;  (2) nonserious 
adverse events (AEs); and (3) exposure to the study intervention under study during 
pregnancy or breastfeeding, and occupational exposure.  
It should  be noted  that the Vaccine  SAE  Reporting  Form  for reporting  of SAE  information 
is not the same as the AE page of the CRF.  When the same data are collected, the forms 
must  be completed  in a consistent  manner.  AEs should  be recorded  using  concise  medical 
terminology  and the same AE term should be used on both the CRF and the Vaccine SAE 
Reporting Form for reporting of SAE information.  
 
Safety Event  Recorded  on the CRF  Reported  on the Vaccine 
SAE Reporting Form to 
Pfizer Safety Within 24 
Hours of Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study 
intervention  under  study 
during pregnancy or 
breastfeeding  All AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding.  All instances  of EDP  are 
reported  (whether  or not 
there is an associated 
SAE).*  
 Note: Instances of EDP or 
EDB  not associated  with an 
AE or SAE  are not captured 
in the CRF.  All instances  of EDB  are 
reported (whether or not 
there is an associated 
SAE).**  
Environmental or 
occupational  exposure  to 
the product under study 
to a non -participant (not 
involving  EDP  or EDB).  None.  Exposure  to a study 
non-participant is not 
collected on the CRF.  The exposure  (whether  or 
not there is an associated 
AE or SAE) must be 
reported.***  
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to Pfizer 
Safety using the Vaccine SAE Reporting Form and EDP Supplemental Form; if the EDP is 
associated  with an SAE,  then the SAE  is reported  to Pfizer  Safety  using  the Vaccine  SAE  Reporting 
Form.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  74  
  
AE and SAE Recording/Reporting  
** EDB  is reported  to Pfizer  Safety  using  the Vaccine  SAE  Reporting  Form,  which  would  also include 
details of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with occupational  exposure  are 
reported to Pfizer Safety using the Vaccine SAE Reporting Form.  
 
 
• When  an AE/SAE  occurs,  it is the responsibility  of the investigator  to review  all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator will then record all  relevant AE/SAE information in the  CRF.  
• It is not acceptable  for the investigator  to send photocopies  of the participant’s 
medical records to Pfizer Safety in lieu of completion of the Vaccine SAE 
Reporting Form/AE/SAE CRF page.  
• There may be instances when copies of medical records for certain cases are 
requested by Pfizer Safety.  In this case, all participant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copies  of the medical 
records before submission to Pfizer Safety.  
• The investigator  will attempt  to establish  a diagnosis  of the event  based  on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis 
(not the individual signs/symptoms) will be documented as the AE or SAE.  
 
 
Assessment of Intensity  
The investigator  will make  an assessment  of intensity  for each AE and SAE  reported 
during the study and assign it to 1 of the following categories:  
• Mild:  An event  that is easily  tolerated  by the participant,  causing  minimal 
discomfort and not interfering with everyday activities.  
• Moderate:  An event  that causes  sufficient  discomfort  and interferes  with normal 
everyday activities.  
• Severe:  An event  that prevents  normal  everyday  activities.  An AE that is assessed 
as severe should not be confused with an SAE.  Severe is a category utilized for 
rating  the intensity  of an event;  and both AEs and SAEs  can be assessed  as severe.  
An event  is defined  as “serious”  when  it meets  at least 1 of the predefined  outcomes  as 
described in the definition of an SAE, NOT when it is rated as severe.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  75  
  
Assessment of Intensity  
 GRADE  If required on the AE page of the CRF, the investigator will use the 
adjectives MILD, MODERATE, SEVERE, to describe the maximum 
intensity  of the AE. For purposes  of consistency,  these  intensity  grades  are 
defined as follows:   
1 MILD  Does  not interfere  with participant's  usual  function.  
2 MODERATE  Interferes  to some  extent  with participant's  usual 
function.  
3 SEVERE  Interferes  significantly  with participant's  usual 
function.  
 
 
Assessment of Causality  
• The investigator  is obligated  to assess  the relationship  between  study  intervention 
and each occurrence of each AE or SAE.  The investigator will use clinical 
judgment to determine the relationship.  
• A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or  arguments  to suggest  a causal  relationship,  rather  than a relationship  cannot 
be ruled out.  
• Alternative  causes,  such as underlying  disease(s),  concomitant therapy,  and other 
risk factors,  as well as the temporal  relationship  of the event  to study  intervention 
administration, will be considered and investigated.  
• The investigator  will also consult  the IB and/or  product  information,  for marketed 
products, in his/her assessment.  
• For each AE/SAE,  the investigator  must  document  in the medical  notes  that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor.  However, it is 
very important that the investigator always make an assessment of causality 
for every  event  before  the initial  transmission  of the SAE  data  to the sponsor.  
• The investigator  may change  his/her  opinion  of causality  in light of follow -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  76  
  
Assessment of Causality  
• The causality  assessment  is one of the criteria  used when  determining  regulatory 
reporting requirements.  
• If the investigator does not know whether or not the study intervention caused the 
event,  then the event  will be handled  as “related  to study  intervention”  for reporting 
purposes, as defined by  the sponsor.  In addition, if the investigator determines that 
an SAE is associated with study procedures, the investigator must record this  
causal relationship in the source documents and CRF, and report such an 
assessment in the dedicated section of the Vaccine SAE Reporting Form and in 
accordance with the SAE reporting requirements.  
 
 
Follow -up of AEs and SAEs  
• The investigator  is obligated  to perform  or arrange  for the conduct  of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
sponsor to elucidate the nature and/or causality of the AE or SAE as fully as 
possible.  This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other healthcare providers.  
• If a participant dies during participation in the study or during a recognized 
follow -up period,  the investigator  will provide  Pfizer  Safety  with a copy  of any 
postmortem findings including histopathology.  
• New  or updated information will be  recorded in the originally  completed CRF.  
• The investigator  will submit  any updated  SAE  data to the sponsor  within  24 hours 
of receipt of the information.  
 
10.3.6.  Reporting  of SAEs  
 
SAE  Reporting  to Pfizer  Safety  via an Electronic  Data  Collection  Tool 
• The primary  mechanism  for reporting  an SAE  to Pfizer  Safety  will be the 
electronic data collection tool.  
• If the electronic  system  is unavailable,  then the site will use the paper  SAE  data 
collection tool (see next section) in order to report the event within 24 hours.  
• The site will enter  the SAE  data into the electronic  system  as soon  as the data 
become available.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  77  
  
SAE  Reporting  to Pfizer  Safety  via an Electronic  Data  Collection  Tool 
• After  the study  is completed  at a given  site, the electronic  data collection  tool will 
be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives  a report  of a new SAE  from  a study  participant  or receives  updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety by telephone.  
 
 
SAE Reporting to Pfizer Safety via Vaccine SAE Reporting Form  
• Facsimile  transmission  of the Vaccine  SAE  Reporting  Form  is the preferred 
method to transmit this information to Pfizer Safety.  
• In circumstances when the facsimile is not working, notification by telephone is 
acceptable  with a copy  of the Vaccine  SAE  Reporting  Form  sent by overnight  mail 
or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete  and sign the Vaccine  SAE  Reporting  Form  pages  within  the designated 
reporting time frames.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  78  
 10.4. Appendix  4: Contraceptive  Guidance  
10.4.1.  Female  Participant  Reproductive  Inclusion  Criteria  
A female  participant  is eligible  to participate  if she is not pregnant  or breastfeeding,  and at 
least 1 of the following conditions applies:  
• Is not a WOCBP  (see definitions  below  in Section  10.4.2). 
OR 
• Is a WOCBP  and using  an acceptable  contraceptive  method  as described  below 
during the intervention period (for a minimum of 28 days after the last dose of 
study intervention).  The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.  
The investigator  is responsible  for review  of medical  history,  menstrual  history,  and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
10.4.2.  Woman  of Childbearing  Potential  
A woman  is considered  fertile  following  menarche  and until becoming  postmenopausal 
unless permanently sterile (see below).  
If fertility  is unclear  (eg, amenorrhea  in adolescents  or athletes)  and a menstrual  cycle  cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in the following  categories  are not considered  WOCBP:  
1. Premenopausal  female  with 1 of the following:  
• Documented  hysterectomy;  
• Documented bilateral salpingectomy;  
• Documented  bilateral  oophorectomy.  
For individuals  with permanent  infertility  due to an alternate  medical  cause  other  than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be 
applied to determining study entry.  
Note: Documentation for any  of the above categories can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method  of documentation  should  be recorded  in the participant’s  medical 
record for the study.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  79  
 2. Postmenopausal  female:  
• A postmenopausal  state is defined  as no menses  for 12 months  without  an alternative 
medical cause.  In addition, a  
• high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal  state in women  under  60 years  of age and not using  hormonal 
contraception or HRT.  
• Female  on HRT  and whose  menopausal  status  is in doubt  will be required  to use 
one of the nonestrogen hormonal highly effective contraception methods if they 
wish to continue their HRT during the study.  Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.  
10.4.3.  Contraception  Methods  
1. Implantable  progestogen -only hormone  contraception  associated  with inhibition  of 
ovulation.  
2. Intrauterine  device.  
3. Intrauterine  hormone -releasing  system.  
4. Bilateral  tubal  occlusion.  
5. Vasectomized  partner:  
• Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the 
absence  of sperm  has been  confirmed.  If not, an additional  highly  effective  method 
of contraception should be used.  The spermatogenesis cycle is approximately  
90 days.  
6. Combined  (estrogen - and progestogen -containing)  hormonal  contraception  associated 
with inhibition of ovulation:  
• Oral;  
• Intravaginal;  
• Transdermal.  
7. Progestogen -only hormone  contraception  associated  with inhibition  of ovulation:  
• Oral;  
• Injectable.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  80  
 8. Sexual abstinence:  
• Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.  The reliability  of sexual  abstinence  needs  to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the 
participant.  
9. Progestogen -only oral hormonal  contraception  where  inhibition  of ovulation  is not the 
primary mode of action.  
10. Male  or female condom  with or  without  spermicide.  
11. Cervical cap, diaphragm, or sponge with spermicide.  
12. A combination  of male  condom  with either  cervical  cap, diaphragm,  or sponge  with 
spermicide (double -barrier methods).  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  81  
 10.5. Appendix  5: Liver  Safety:  Suggested  Actions  and Follow -up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in 
transaminases)  are termed  “tolerators,”  while  those  who show  transient  liver injury,  but adapt 
are termed “adaptors.”  In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participants fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are an “adaptor” or are “susceptible.”  
LFTs are not required as a routine safety monitoring procedure in this study.  However, 
should  an investigator  deem  it necessary  to assess  LFTs  because  a participant  presents  with 
clinical signs/symptoms, such LFT results should be managed and followed as described 
below.  
In the majority  of DILI  cases,  elevations  in AST  and/or  ALT  precede  TBili  elevations 
(>2 × ULN) by several days or weeks.  The increase in TBili typically occurs while 
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and TBili values will be  
elevated  within  the same  laboratory  sample).  In rare instances,  by the time TBili  elevations 
are detected, AST/ALT values might have decreased.  This occurrence is still regarded as a 
potential DILI.  Therefore, abnormal elevations in either AST OR ALT in addition to TBili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.  
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual  baseline  values  and underlying  conditions.  Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants  with AST/ALT  and TBili  baseline  values  within  the normal  range  who 
subsequently present with AST OR ALT values >3 × ULN AND a TBili value  
>2 × ULN  with no evidence of  hemolysis and an  alkaline phosphatase value  
<2 × ULN  or not available.  
• For participants  with baseline  AST  OR ALT  OR TBili  values  above  the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values  >2 times  the baseline  values  AND  >3 × ULN;  or >8 × ULN  (whichever  is 
smaller).  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  82  
 • Preexisting values of TBili above the normal range: TBili level increased from 
baseline  value  by an amount  of at least 1 × ULN  or if the value  reaches  >3 × ULN 
(whichever is smaller).  
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed 
individually  based  on clinical  judgment;  any case where  uncertainty  remains  as to whether  it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
The participant should return to the investigator site and be evaluated as soon as possible, 
preferably  within  48 hours  from  awareness  of the abnormal  results.  This evaluation  should 
include laboratory tests, detailed history, and physical assessment.  
In addition to repeating measurements of AST and ALT and TBili for suspected cases of 
Hy’s law, additional laboratory tests should include albumin, CK, direct and indirect 
bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase.  Consideration should 
also be given  to drawing  a separate  tube of clotted  blood  and an anticoagulated  tube of blood 
for further testing, as needed, for further contemporaneous analyses at the time of the 
recognized  initial  abnormalities  to determine  etiology.  A detailed  history,  including  relevant 
information, such as review of ethanol, acetaminophen/paracetamol (either by itself or as a 
coformulated product in prescription or over -the-counter medications), recreational drug, 
supplement (herbal) use and consumption, family history, sexual history, travel history, 
history of contact with a jaundiced person, surgery, blood transfusion, history of liver or 
allergic disease, and potential occupational exposure to chemicals, should be collected.  
Further  testing  for acute  hepatitis  A, B, C, D, and E infection  and liver imaging  (eg, biliary 
tract) and collection of serum samples for acetaminophen/paracetamol drug and/or protein 
adduct levels may be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and 
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other  reason  for the LFT abnormalities  has yet  been  found.  Such  potential  DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable  investigations  have  been  received  and have  excluded  an alternative  etiology.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  83  
 10.6. Appendix  6: Protocol  Amendment  History  
The Protocol  Amendment  Summary  of Changes  Table  for the current  amendment  is located 
directly  before the table of contents (TOC).  The protocol amendment summary  of changes 
tables for past amendment(s) can be found below:  
Amendment  2 (11 April 2022)  
Overall Rationale for the Amendment:  Study  sample size and statistical analyses have 
been  modified  based  on a strategic  decision  to describe  the safety  and immunogenicity  in 
nonpregnant women, with a plan for a future study to evaluate the safety and 
immunogenicity in pregnant women.  
 
Section  # and Name  Description of Change  Brief Rationale  
Section 1.1:  Synopsis  
Section 2: Introduction 
Section  2.1: Study  Rationale 
Section 2.2.2: Maternal  
Immunization  as an Approach  to 
Prevent Disease in Infants and 
Pregnant Women  
Section 2.3.1: Risk Assessment 
Section  3: Objectives,  Estimands, 
and Endpoints  
Section 4.1: Overall Design 
Section  4.3: Justification  for 
Dose  
Section  5.2: Exclusion  Criteria 
Section 6.5.3: Recording 
Nonstudy Vaccinations and 
Concomitant Medications 
Section 9.1.1: Statistical 
Hypotheses  
Section  9.1.2:  Estimands 
Section  9.2: Sample  Size 
Determination  
Section  9.4.2:  Immunogenicity 
Analyses  • Modified  the primary 
immunogenicity 
objective and 
estimands to align 
with strategic 
decision of 
evaluating the 
immunogenicity 
interference with 
coadministration of 
Tdap and GBS6.  
• Revised the study 
sample size to align 
with modified  safety 
and immunogenicity 
objective.  
• Modified the 
hypothesis -based 
noninferiority  testing 
analysis for the 
primary 
immunogenicity 
endpoints to 
descriptive analysis 
due to the change in 
the primary study 
immunogenicity 
objective.  
• Modified  appropriate 
statistical sections 
due to updates to the  • The study  aims  to have 
a sufficient number of 
participants in order to 
describe  the safety  and 
immunogenicity of 
coadministration of 
GBS6 and Tdap.  
• The study design is 
descriptive  in nature, 
and descriptive 
statistics will be 
provided for the 
primary safety and 
primary 
immunogenicity 
endpoints.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  84  
  
Section  # and Name  Description of Change  Brief Rationale  
 primary 
immunogenicity 
objectives and 
estimands.   
Section 1.1: Synopsis 
Section  1.3: Schedule  of 
Activities  
Section 2.3.3: Overall 
Benefit/Risk  Conclusion  
Section  3: Objectives,  Estimands, 
and Endpoints  
Section 7.2: Participant 
Discontinuation/Withdrawal 
From the Study  
Former  Section  8.1.3:  GBS 
Microbiological Cultures 
Section 8.1.3: Biological 
Samples  
Section 8.11.1: Visit 1 – 
Vaccination (Day  1) 
Section  8.11.2:  Visit  2 – 1-Month 
Follow -up Visit (28 -38 Days 
After Visit 1)  • Removed swabs for 
GBS  microbiological 
cultures.  • Due to the reduction  in 
study participants, 
there  is no added  value 
in taking the 
microbiological 
cultures.  
Section 1.1: Synopsis 
Section  1.3: Schedule  of 
activities  
Section  3: Objectives,  Estimands, 
and Endpoints  
Section 4.1: Overall Design 
Section 6.5.3: Recording 
Nonstudy Vaccinations and 
Concomitant Medications 
Section 8.1: Efficacy and/or 
Immunogenicity Assessments 
Section 8.3.1: Time Period and 
Frequency  for Collecting  AE and 
SAE Information  
Former  Section  8.11.3:  Visit  3 – 
6-Month Telephone Call 
Follow -up Visit (160 -200 Days 
After Visit 1)  
Section 9.1.2: Estimands  • Modified the study 
follow -up period  for 
participants to 
approximately  
1 month after 
vaccination  to align 
with the study 
objectives.  • Safety  will be assessed 
through 1 month after 
vaccination. Immune 
responses  to GBS6  and 
Tdap antigens will be 
measured 1 month  
after vaccination.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  85  
  
Section  # and Name  Description of Change  Brief Rationale  
Section  8.1.1:  GBS  Vaccine 
Antibody Testing  
Section  8.1.2:  Tdap  Antibody 
Testing  • Added  an unblinded 
statistician  who will 
identify  participants 
from the dose 
groups.  • The addition of an 
unblinded statistician 
will allow study 
participants to be 
divided by 
immunogenicity 
assessment in order to 
decrease  the number  of 
assays required to be 
analyzed.  
Document History  
Section 5.2: Exclusion Criteria 
Section 5.3.1: Contraception 
Section 5.5: Criteria for 
Temporarily Delaying 
Enrollment/Randomization/Study 
Intervention Administration of 
Study Intervention  
Section  6: Study  Intervention(s) 
and Concomitant Therapy 
Section 7.2.1: Withdrawal of 
Consent  
Section  8.2.5:  Pregnancy  Testing 
Section 8.3: Adverse Events and 
Serious Adverse Events  
Section 8.3.1: Time Period and 
Frequency  for Collecting  AE and 
SAE Information  
Section 8.3.5: Environmental 
Exposure, Exposure During 
Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Section  10.1.3:  Informed 
Consent Process  
Section  10.1.7:  Source 
Documents  
Section 10.1.10: Sponsor’s 
Qualified Medical Personnel 
Section  10.3.2:  Definition  of an 
SAE 
Section 10.3.5: 
Recording/Reporting and 
Follow -up of AEs and/or  SAEs  • Updated  wording  to 
match mandatory 
text from the new 
protocol template.  • These changes were 
incorporated  to align 
with the protocol 
template changes.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  86  
  
Section  # and Name  Description of Change  Brief Rationale  
Section 10.6: Appendix 6: 
Protocol  Amendment  History    
 
Amendment  1 (22 January  2021)  
Overall Rationale for the Amendment: The GBS6 dose formulation has been updated to 
remove  AlPO 4 since  interim  data from  Study  C1091002  show  acceptable  immune  responses 
were achieved with the formulation that did not contain AlPO 4. 
 
Section # 
and Name  Description of Change  Brief Rationale  
Section 1 
Section 4.1 
Section 4.3 
Section 6.1 The GBS6  dose formulation  has 
been updated to remove AlPO 4 The GBS6 dose formulation has been 
updated  to remove  AlPO 4 since  interim 
data from Study C1091002 shows 
acceptable immune responses were 
achieved with the formulation that did 
not contain AlPO 4. 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  87  
 10.7. Appendix  7: Abbreviations  
The following  is a list of abbreviations  that may be used in the protocol.  
 
Abbreviation  Term  
ACIP  Advisory  Committee on Immunization Practices  
ADE  adverse  device  effect  
AE adverse  event  
AlPO 4 aluminum phosphate  
ALT  alanine aminotransferase  
AST aspartate aminotransferase  
BLQ  below the limit of quantitation  
CBER  Center  for Biologics  Evaluation  and Research  (United  States)  
CFR Code of Federal Regulations  
CI confidence  interval  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CK creatine  kinase  
CONSORT  Consolidated  Standards  of Reporting  Trials  
CPS capsular  polysaccharide  
CRF case report  form 
CRM 197 cross -reactive  material  197 
CRO  contract research organization  
CSR clinical study  report  
DILI  drug-induced  liver injury  
DNA  deoxyribonucleic  acid 
DTd diphtheria toxoid  
DU dispensable  unit 
EC ethics  committee  
ECG  electrocardiogram  
eCRF  electronic case report form  
e-diary  electronic diary  
E-DMC  external data monitoring committee  
EDP exposure during pregnancy  
EMA  European  Medicines  Agency  
EOD  early -onset  disease  
EU European  Union  
EudraCT  European  Clinical  Trials  Database  
EU/mL  endotoxin  units  per milliliter  
FDA  Food  and Drug  Administration  (United  States)  
FHA  filamentous  hemagglutinin  
FIH first-in-human  
FIM fimbriae  
FSH follicle -stimulating  hormone  
GBS  group  B streptococcus  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  88  
  
Abbreviation  Term  
GBS6  group  B streptococcus  6-valent  polysaccharide  conjugate  vaccine  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
GMC  geometric mean concentration  
GMFR  geometric  mean  fold rise 
GMR  geometric  mean  ratio 
GMT  geometric  mean  titer 
HIPAA  Health Insurance Portability  and Accountability  Act 
HRT  hormone  replacement  therapy  
IAP intrapartum antibiotic prophylaxis  
IB investigator’s  brochure  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  
ID identification  
IgG immunoglobulin G 
IND investigational  new drug 
INR international  normalized  ratio 
IP manual  investigational  product  manual  
IPAL  Investigational Product Accountability  Log 
IRB institutional  review  board  
IRT interactive response technology  
ISF investigator  site file 
IU/mL  international units per milliliter  
IWR  interactive  Web -based  response  
Lf flocculation  units  
LFT liver function  test 
LLOQ  lower limit of quantitation  
LMIC  low- and middle -income  country  
Ln natural  logarithm  
LOD  late-onset  disease  
MAE  medically  attended adverse event  
MCAR  missing  completely  at random  
MedDRA  Medical Dictionary  for Regulatory  Activities  
mITT  modified  intent -to-treat 
mIU/mL  milli -international  units  per milliliter  
N/A not applicable  
NaCl  sodium chloride  
PRN  pertactin  
PT prothrombin time 
RCDC  reverse cumulative distribution curve  
RSV  respiratory  syncytial  virus  
SADE  serious  adverse  device  effect  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  89  
  
Abbreviation  Term  
SAE serious  adverse  event  
SAP statistical  analysis  plan 
SoA schedule  of activities  
SOP standard operating procedure  
SRM  study  reference  manual  
SRSD  single  reference  safety  document  
SUSAR  suspected  unexpected  serious  adverse  reaction  
TBili  total bilirubin  
Td tetanus  and diphtheria  vaccine  
Tdap  tetanus  toxoid,  diphtheria  toxoid,  and acellular  pertussis  vaccine  
TTd tetanus toxoid  
ULN  upper  limit  of normal  
US United  States  
USPI  United  States  prescribing  information  
WOCBP  woman/women  of childbearing  potential  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  90  
 11. REFERENCES  
 
1 Dangor  Z, Lala SG, Cutland  CL, et al. Burden  of invasive  group  B streptococcus  disease 
and early neurological sequelae in South African infants. PLoS One 
2015;10(4):e0123014.  
2 Madrid L, Seale AC, Kohli -Lynch M, et al. Infant group B streptococcal disease 
incidence  and serotypes  worldwide:  systematic  review  and meta -analyses.  Clin Infect 
Dis 2017;65(Suppl 2):S160 -72. 
3 Lin FYC,  Philips  JB 3rd, Azimi  PH, et al. Level  of maternal  antibody  required  to protect 
neonates against early -onset disease caused by group B streptococcus type Ia: a 
multicenter, seroepidemiology study. J Infect Dis 2001;184(8):1022 -8. 
4 Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B 
streptococcal  disease  in the United  States,  1999 -2005.  JAMA  2008;299(17):2056 -65. 
5 Edmond  KM, Kortsalioudaki  C, Scott  S, et al. Group  B streptococcal  disease  in infants 
aged younger than 3 months: systematic review and meta -analysis. Lancet 
2012;379(9815):547 -56. 
6 Skoff  TH, Farley  MM,  Petit S, et al. Increasing  burden  of invasive  group  B 
streptococcal disease in nonpregnant adults, 1990 -2007. Clin Infect Dis 
2009;49(1):85 -92. 
7 Lamagni  TL, Keshishian  C, Efstratiou  A, et al. Emerging  trends  in the epidemiology  of 
invasive group B streptococcal disease in England and Wales, 1991 -2010. Clin Infect 
Dis 2013;57(5):682 -8. 
8 Deutscher  M, Lewis  M, Zell ER, et al. Incidence  and severity  of invasive  
Streptococcus  pneumoniae , group  A streptococcus,  and group  B streptococcus  infections 
among pregnant and postpartum women. Clin Infect Dis 2011;53(2):114 -23. 
9 Edwards MS, Nizet V, Baker CJ. Group B streptococcal infections. In: Remington JS, 
Klein JO, Wilson CB, et al, eds. Infectious diseases of the fetus and newborn. 7th ed. 
Amsterdam,  the Netherlands:  Elsevier;  2011:419 -69. Available  from:  http://dx.doi.org/  
10.1016/B978 -1-4160 -6400 -8.00012 -2. Accessed: 15 Sep 2015.  
10 Baker  CJ. The spectrum  of perinatal  group  B streptococcal  disease.  Vaccine 
2013;31(Suppl 4):D3 -6. 
11 Smith  EM, Khan  MA, Reingold  A, et al. Group  B streptococcus  infections  of soft tissue 
and bone in California adults, 1995 -2012. Epidemiol Infect 2015;143(15):3343 -50. 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  91  
  
12 Natarajan  P, Poretz  DM. The increasing  threat  of group  B streptococcus  infection  in 
adults [abstract 738]. Open Forum Infect Dis 2014;1(Suppl 1):S208.  
13 Munoz  FM. Current  challenges  and achievements  in maternal  immunization  research. 
Front Immunol 2018;9:436.  
14 Berenson  AB, Hirth  JM, Rahman  M, et al. Maternal  and infant  outcomes  among  women 
vaccinated against pertussis during pregnancy. Hum Vaccin Immunother 
2016;12(8):1965 -71. 
15 Swamy  GK, Beigi  RH. Maternal  benefits  of immunization  during  pregnancy.  Vaccine 
2015;33(47):6436 -40. 
16 Englund  JA. The influence  of maternal  immunization  on infant  immune  responses. 
J Comp Pathol 2007;137(Suppl 1):S16 -9. 
17 Zaman  K, Roy E, Arifeen  SE, et al. Effectiveness  of maternal  influenza  immunization  in 
mothers and infants. N Engl J Med 2008:359(15):1555 -64. 
18 Madhi  SA, Cutland  CL, Kuwanda  L, et al. Influenza  vaccination  of pregnant  women  and 
protection of their infants. N Engl J Med 2014;371(10):918 -31. 
19 Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus 
diphtheria  and acellular  pertussis  (Tdap)  immunization  during  pregnancy  in mothers  and 
infants: a randomized clinical trial. JAMA 2014;311(17):1760 -9. 
20 Layton  JB, Butler  AM, Li D, et al. Prenatal  Tdap  immunization  and risk of maternal  and 
newborn adverse events. Vaccine 2017;35(33):4072 -8. 
21 Harper SA, Fukuda K, Uyeki TM, et al; Centers for Disease Control and Prevention 
Advisory  Committee  on Immunization  Practices.  Prevention  and control  of influenza: 
recommendations of the Advisory Committee on Immunization Practices (ACIP) 
[erratum appears in MMWR Recomm Rep 2004;53(32):743]. MMWR Recomm Rep 
2004;53(RR -6):1-40. Update appears in MMWR Recomm Rep 2005;54(RR -8):1-40. 
22 Lindsey B, Kampmann B, Jones C. Maternal immunization as a strategy to decrease 
susceptibility  to infection  in newborn  infants.  Curr Opin  Infect  Dis 2013;26(3):248 -253. 
23 Centers for Disease Control and Prevention. Updated recommendations for use of 
tetanus  toxoid,  reduced  diphtheria  toxoid,  and acellular  pertussis  vaccine  (Tdap)  in 
pregnant women --Advisory Committee on Immunization Practices (ACIP), 2012. 
MMWR Morb Mortal Wkly Rep 2013;62(7):131 -5. 
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  92  
  
24 Australian  Government  Department  of Health.  Pertussis  (whooping  cough).  In: 
Australian immunisation handbook. Available from: 
https://immunisationhandbook.health.gov.au/vaccine -preventable -diseases/ 
pertussis -whooping -cough. Updated: 20 Sep 2019. Accessed: 24 Oct 2019.  
25 Bekker V, Bijlsma MW, van de Beek D, et al. Incidence of invasive group B 
streptococcal  disease  and pathogen  genotype  distribution  in newborn  babies  in the 
Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis 
2014;14(11):1083 -89. 
26 Baker  CJ, Carey  VJ, Rench  MA, et al. Maternal  antibody  at delivery  protects  neonates 
from early onset group B streptococcal disease. J Infect Dis 2014;209(5):781 -8. 
27  Dangor  Z, Kwatra  G, Izu A, et al. Correlates  of protection  of serotype -specific  capsular 
antibody  and invasive group B streptococcus disease in South African infants. Vaccine 
2015;33(48):6793 -9. 
28 Fabbrini M, Rigat F, Rinaudo CD, et al. The protective value of maternal group B 
streptococcus antibodies: quantitative and functional analysis of naturally acquired 
responses  to capsular  polysaccharides  and pilus  proteins  in European  maternal  sera. Clin 
Infect Dis 2016;63(6):746 -53. 
29 Lin FY, Philips  JB 3rd, Azimi  PH, et al. Level  of maternal  antibody  required  to protect 
neonates against early -onset disease caused by group B streptococcus type Ia: a 
multicenter, seroepidemiology study. J Infect Dis 2001;184(8):1022 -8. 
30  Lin FYC, Weisman LE, Azimi PH, et al. Level of maternal IgG anti -group B 
streptococcus type III antibody  correlated with protection of neonates against 
early -onset  disease  caused  by this pathogen.  J Infect  Dis 2004;190(5):928 -34. 
31 Dzanibe S, Madhi SA. Systematic review of the clinical development of group B 
streptococcus  serotype -specific  capsular  polysaccharide -based  vaccines.  Expert  Rev 
Vaccines 2018;17(7):635 -51. 
 
32  Madhi SA, Cutland CL, Jose L, et al. Safety  and immunogenicity  of an investigational 
maternal  trivalent  group  B streptococcus  vaccine  in healthy  women  and their infants:  a 
randomised phase 1b/2 trial. Lancet Infect Dis 2016;16(8):923 -34. 
 
33 Fluarix  [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2020.  
34 Afluria [package insert]. Summit, NJ: Seqirus; 2020.  
35 Afluria Quadrivalent [package insert]. Summit, NJ: Seqirus; 2020.  
Group  B Streptococcus  6-Valent  Polysaccharide  Conjugate  Vaccine  (GBS6) 
Protocol C1091005  
Final  Protocol  Amendment  3, 04 October  2022  
PFIZER  CONFIDENTIAL  
Page  93  
  
36 US Food  and Drug  Administration.  Guidance  for industry: toxicity  grading  scale  for 
healthy  adult  and adolescent  volunteers  enrolled  in preventive  vaccine  clinical  trials. 
Rockville, MD: Center for Biologics Evaluation and Research; September 2007.  
 
 Signed By: Date(GMT)  Signing Capacity   
Document Approval Record  
 
 
C1091005  Clinical  Protocol  Amendment  3 Clean  Copy,  04 Oct 2022  
 
A PHASE 2B, PLACEBO -CONTROLLED, RANDOMIZED, OBSERVE 
R-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, A 
ND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOC 
OCCUS  VACCINE  WHEN  ADMINISTERED  CONCOMITANTLY  WITH 
TETANUS,  DIPHTHERIA,  AND  ACELLULAR  PERTUSSIS  VACCINE  ( 
TDAP)  IN HEALTHY  NONPREGNANT  WOMEN  18 THROUGH  49 YE 
ARS OF AGE  
 
 
PPD   
PPD  04-Oct-2022  14 45 29 Final  Approval  
 
04-Oct-2022  14 53 49 Final  Approval  Document  Name: 
Document Title:  